Study Title: Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and 
Drug Interactions 
 
Document Title:  Clinical Study Protocol – Study N o. SCR- 016 
 
Document Date: 19 March  2024  
 
Study ID: [REMOVED] 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 1 of 72 
  
 CLINICAL STUDY PROTOCOL 
  Clinical Study to Evaluate Cannabid iol Liver Enzyme Elevations and 
Drug Interactions  
 
PROTOCOL NO. SCR-016 
  
Sponsor: U.S. Food and Drug Administration 
White Oak Building #64, Room 2072 10903 New Hampshire Avenue Silver Spring, MD 20993  
Sponsor Study Lead: David Strauss, MD, PhD 
U.S. Food and Drug Administration Telephone: 301-796-6323 Email: david.strauss@fda.hhs.gov 
  
Sponsor Medical Monitor: Keith Burkhart, MD 
U.S. Food and Drug Administration 301-796-2226 Email: keith.burkhart@fda.hhs.gov 
  
Project Manager: Jeffry Florian, PhD  
U.S. Food and Drug Administration  Telephone: 301-796-4847  Email: jeffry.florian@fda.hhs.gov 
  
 
Version of Protocol: 3.0 
 
Date of Protocol: March 19, 2024 
 
CONFIDENTIAL 
The concepts and information contained in th is document or generated during the study are 
considered proprietary and may not be disclosed in whole or in part without the expressed 
written consent of the U.S. Food and Drug Administration. 
U.S. FOOD AND DRUG ADMINISTRATION Protocol Number: SCR-016
(Version 3.0)
CONFIDENTIAL Page 2of 72SPONSOR SIGNATURE PAGE
This study will be conduc ted with the highest respect for the individual participants in 
accordance with the requirements of this clinical  study protocol and also in accordance with the 
following: 
xThe ethical principles that  have their origin in th e Declaration of Helsinki;
xInternational Council for Harmonisation (ICH) harmonised tripartite gui deline E6 (R2): Good 
Clinical Practice; and
xAll applicable laws and regulations, incl uding without limitation, data  privacy laws and 
compliance with appropriate regulations, incl uding human subject research requirements set 
forth by the Institutional Review Board (IRB). 
David Strauss, MD, PhD
U.S. Food and Drug Administration Date

U.S. FOOD AND DRUG ADMINISTRATION Protocol Number: SCR-016
(Version 3.0)
CONFIDENTIAL Page 3of 72INVESTIGATOR SIGNATURE PAGE
I confirm that I have read and th at I understand this protocol, the investigator brochure, and other 
product information provided by the sponsor. I agr ee to conduct this study in accordance with the 
requirements of this protocol a nd also protect the rights, safet y, privacy, and well-being of study 
subjects in accordance with the following: 
xThe ethical principles that  have their origin in th e Declaration of Helsinki;
xICH harmonised tripartite guideline E6 (R2): Good Clinical Practice;
xAll applicable laws and regulations, incl uding without limitation data  privacy laws and 
regulations; 
xHuman subject research requirements set forth by the IRB; 
xRegulatory requirements for repor ting of serious adverse events (SAEs) defined in Section  
of this protocol; and 
xTerms outlined in the Clinical Study Site Agreement.
I further authorize that my pers onal information may be processed and transferred in accordance 
with the uses contemplated in  Section 6 of this protocol. 
Melanie Fein, MD  
Principal Investigator 
                        Date

U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 4 of 72 
  
 Table of Contents 
SPONSOR SIGNATURE PAGE ........................................................................................................ ............ 2  
INVESTIGATOR SIGNATURE PAGE ................................................................................................... ......... 3  
LIST OF TABLES ................................................................................................................ ........................ 6  
PROTOCOL SYNOPSIS ............................................................................................................. .................. 7  
1. INTRODUCTION .................................................................................................................. ............ 16  
2. STUDY OBJECTIVES .............................................................................................................. ........... 17  
3. ENDPOINTS ..................................................................................................................... ............... 17  
3.1 PART 1 ............................................................................................................................. .................................. 17  
Primary E ndpoint: ............................................................................................................. .................. 17  
Secondary E ndpoint:  ........................................................................................................... ................ 17  
Exploratory E ndpoints: ........................................................................................................ ................ 17  
3.2 PART 2 (DRUG-DRUG INTERACTIONS ) ...................................................................................................................... 17  
Primary Endpoints: ............................................................................................................ .................. 18  
Secondary E ndpoints: .......................................................................................................... ................ 18  
Exploratory E ndpoints: ........................................................................................................ ................ 18  
4. INVESTIGATIONAL PLAN .......................................................................................................... ....... 18  
4.1 STUDY DESIGN ............................................................................................................................... ........................ 18  
4.1.1. Risk/Benefit ........................................................................................................... .................... 21  
4.2 SELECTION OF STUDY POPULATION  ............................................................................................................................ 2 3 
4.2.1 Inclusion Criteria....................................................................................................... .................. 23  
4.2.2 Exclusion Criteria ...................................................................................................... .................. 24  
4.3 SCREENING FAILURES  .............................................................................................................................. ................ 27  
4.4 TERMINATION OF STUDY OR INVESTIGATIONAL SITE ...................................................................................................... 27  
4.4.1 Criteria for Term ination of the Study ................................................................................... ...... 27  
4.4.2 Criteria for Termination of the Investi gational Site ....................................................................  27 
4.5 CRITERIA FOR SUBJECT WITHDRAWAL  ........................................................................................................................ 28  
4.5.1 Handling of Withdrawals ................................................................................................. .......... 29  
4.5.2 Replacement of Subj ects ................................................................................................. ........... 29  
4.6 STUDY VISITS............................................................................................................................... .......................... 30  
4.6.1 Recruitment ............................................................................................................. ................... 30  
4.6.2 Compensation ............................................................................................................ ................ 30  
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 5 of 72 
  
 4.6.3 Screening ............................................................................................................... ..................... 30  
4.6.4 Study Periods ........................................................................................................... ................... 31  
4.7 STUDY PROCEDURES  .............................................................................................................................. ................. 33  
4.7.1 Pharmacokinetic Assessments ............................................................................................. ...... 33  
4.7.2 Endocrine Assessments ................................................................................................... ........... 35  
4.7.2 Lipid Assessments ....................................................................................................... ................ 35  
4.7.2 Proteomics Assessments .................................................................................................. .......... 35  
4.7.3 Safety Assessments ...................................................................................................... .............. 36  
4.7.4 Demographics and Medical History ........................................................................................ ... 41  
4.8 STUDY TREATMENTS  .............................................................................................................................. ................. 41  
4.8.1 Dose Select ion and Rational ............................................................................................. .......... 41  
4.8.2 Treatments Admini stered and Sc hedule ....................................................................................  42 
4.8.3 Management of Clinical Supplies ......................................................................................... ...... 44  
4.8.4 Blinding ................................................................................................................ ...................... 44  
4.8.5 Treatment Compliance .................................................................................................... ........... 45  
4.8.6 Prior and Concom itant Medi cations........................................................................................ ... 45  
4.8.7 Subject Restrictions .................................................................................................... ................ 45  
4.9 STATISTICAL METHODS ............................................................................................................................... ............. 46  
4.9.1 Sample Size ............................................................................................................. .................... 47  
4.9.2 Analysis Populations .................................................................................................... ............... 47  
4.9.3 General Statistical Considerations ...................................................................................... ....... 47  
4.9.4 Subject Disposition ..................................................................................................... ................ 48  
4.9.5 Demographics and Base line Characte ristics .............................................................................. 48 
4.9.6 Primary and Se condary Analyses .......................................................................................... ..... 48  
4.9.10 Safety Analyses ........................................................................................................ ................ 49  
4.9.11 Interim Analyses ....................................................................................................... ................ 50  
4.9.12 Missing Data ........................................................................................................... ................. 50  
4.10  DATA QUALITY ASSURANCE  .............................................................................................................................. ..... 51  
4.11  DATA SHARING  .............................................................................................................................. ...................... 51  
5. ETHICAL CONSIDERATIONS ........................................................................................................ ..... 51  
5.1 ETHICAL CONDUCT OF THE STUDY  ............................................................................................................................. 51 
5.2 INSTITUTIONAL REVIEW BOARD (IRB) ........................................................................................................................ 51 
6. ADMINISTRATIVE PROCEDURES .....................................................................................................  52 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 6 of 72 
  
 6.1 RESPONSIBILITIES OF THE INVESTIGATOR  ..................................................................................................................... 52  
6.1.1 Form FDA 1572 ........................................................................................................... ................ 52  
6.1.2 Adherence to Prot ocol ................................................................................................... ............. 52  
6.1.3 Reporting Requirements................................................................................................... .......... 52  
6.1.4 Source Documentation .................................................................................................... ........... 52  
6.1.5 Retention of Records .................................................................................................... .............. 52  
6.1.6 Financial Disclosu re and Obli gations .................................................................................... ...... 53  
6.2 CONFIDENTIALITY AND DISCLOSURE OF DATA .............................................................................................................. 53  
6.3 SUBJECT CONSENT  .............................................................................................................................. ................... 54  
6.4 DATA COLLECTION  .............................................................................................................................. ................... 54  
6.5 PUBLICATIONS  .............................................................................................................................. ......................... 54  
7. STUDY MANAGEMENT .............................................................................................................. ..... 55  
7.1 MONITORING  .............................................................................................................................. .......................... 55  
7.2 MANAGEMENT OF PROTOCOL AMENDMENTS AND DEVIATIONS  ...................................................................................... 55  
7.2.1 Modification of the Pr otocol ............................................................................................ .......... 56  
7.2.2 Protocol Violatio ns and Deviations ...................................................................................... ...... 56  
REFERENCE LIST ................................................................................................................ ..................... 57  
8. APPENDICES .................................................................................................................... ............... 59  
APPENDIX A – SCHEDULE OF EVENTS – PART 1 .................................................................................................................. 59  
APPENDIX B – SCHEDULE OF EVENTS – PART 2.1 (CITALOPRAM ) .......................................................................................... 62  
APPENDIX B – SCHEDULE OF EVENTS – PART 2.2 (MORPHINE ) ............................................................................................ 64  
APPENDIX C – LIST OF ABBREVIATIONS  ............................................................................................................................ 6 6 
LIST OF ABBREVIATIONS ......................................................................................................... ......... 66  
APPENDIX D – DRUG-INDUCED LIVER INJURY ASSESSMENT  .................................................................................................. 67  
APPENDIX E – PROTOCOL REVISION HISTORY  .................................................................................................................... 68  
PROTOCOL REVISION HISTORY ..................................................................................................... .. 68 
 
 
LIST OF TABLES  
TABLE 4-1:  CLINICAL LABORATORY TESTS & DIAGNOSTIC SCREENING TESTS  ........................................ 3940  
 
  
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 7 of 72 
  
 PROTOCOL SYNOPSIS 
Protocol Number: SCR-016 
Title: Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions  
Investigators:  Melanie Fein, MD     
Study Phase: 1 
Study Period:  This is a 2-part study. The duration of study participation will be up to 36 days 
(excluding the screening period) for Part 1. The duration of study particip ation will be up to 24 
days (excluding the screening period) for Part 2. 
Study Site: Spaulding Clinical Research Unit, West Bend, Wisconsin 
Background and Motivation:   
The cannabis plant contains bioactive compounds known as cannabinoids; delta-9 
tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most  prevalent cannabinoids in 
most varieties of cannabis.1 The Agricultural Improvement Act (Farm Bill) of 2018 removed 
hemp, defined as cannabis and derivatives of can nabis with extremely low concentrations of 
THC, from the definition of marijuana in the Controlled Substances Act.1 Following this, many 
CBD products have been made available to consumers. Howe ver, hemp products remain 
subject to regulation under the Federal Food Drug  & Cosmetic Act, when  applicable (e.g., as 
drugs, foods, dietary supplement s, cosmetics, veterinary products) and the growing CBD 
products market raises various safety co ncerns, especially with long-term use.1 
CBD is available as a prescription drug product fo r the treatment of seizures associated with 
Lennox-Gastaut syndrome, Dravet syndrom e, or tuberous sclerosis complex.2 At labeled doses 
up to 25 mg/kg/day, an increased risk of liver enzyme elevation and drug-induced liver injury 
has been observed.2,3 However, only limited evaluations of the risk of liver enzyme elevation of 
daily, lower dose CBD use are available.3,4 The potential for liver enzyme elevations with CBD 
doses in unapproved consumer products highlights a need for further research to quantify risks 
at these doses. In addition, CBD has the capacity to inhibit cytochrome P450 enzymes and uridine 5’-diphospho-glucuronosyltransferases, lead ing to potential drug-dr ug interactions with 
multiple common medications.
2,5 The clinical significance of many of these interactions is also 
unclear. Furthermore, nonclini cal studies have suggested the potential for CBD to cause 
reproductive and endocrine effects.6-8 As such, additional high- quality clinical pharmacology 
studies are needed to further ch aracterize CBD's safety profile. 
This study will be divided into two parts.  
In Part 1, 200 healthy subjects will be randomized  to 5 mg/kg/day of CBD (150 subjects) or 
placebo (50 subjects) for 4 weeks with weekly laboratory assessments to characterize the 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 8 of 72 
  
 percentage of participants with liver enzy me elevation (primary endpoint) or meeting 
withdrawal criteria for potential drug-induced liver injury (secondary endpoint). Additional 
secondary endpoints include the change from base line to after 4 weeks of daily CBD dosing for 
male reproductive (testosterone and inhibin B) and thyroid hormones (thyroid stimulating hormone [TSH], triiodothryroni ne [T3] and thryroxine [T4]) as secondary endpoints. 
Exploratory endpoints include additional charact erization of liver findings and other blood 
biomarkers. 
In Part 2, 40 healthy subjects will receive either oral citalopram (20 subjects) or morphine (20 
subjects) at baseline and then again after receiving CBD 5 mg/kg/day to characterize the effect of daily cannabidiol use on the plasma concentr ation of citalopram a nd morphine. Citalopram 
was selected because it is a common prescription medication for depression and anxiety that is 
metabolized by CYP2C19 and CYP3A4,
9 which CBD inhibits.5 Morphine was selected because 
it is a common opioid analgesic that is metabolized by UGT2B7,10 which CBD inhibits.5 
Objectives:  
Part 1:  
To characterize the effects of daily cannabidiol use at a dose within the range of what 
consumers are taking as unapproved cannabidiol  products on liver enzyme elevations and 
endocrine measures.   
Part 2:  
To characterize the effects of daily cannabidiol use at a dose within the range of what 
consumers are taking as unapproved canna bidiol products on drug interactions.  
Endpoints:  
Part 1:  
x Primary Endpoint:  
x Percentage of participants with an ALT (based on consensus criteria*) or AST 
liver enzyme elevation greater than three times the upper limit of normal (>3 × 
ULN)  
x Secondary Endpoints:  
x Percentage of participants meeting wit hdrawal criteria for potential drug-induced 
liver injury (DILI) 
x Change from baseline in total testosterone and inhibin B in male participants 
after CBD administration compared to placebo 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 9 of 72 
  
 x Change from baseline in thyroid stimulating hormone (TSH), total T3, and free 
T4 after CBD administration compared to placebo 
x Exploratory Endpoints:  
x Assessment of liver-related adverse events  
x Summary of CBD and metabolite pharmacokinetics 
x Proportion of subjects with  abnormal laboratory (e.g., liver, endocrine) tests  
x Changes in additional laboratory and plasma proteome assessments 
*Consensus criteria for ALT elevation: ULN for ALT will be 33 U/L for males and 25 
U/L for females 
Part 2 (Drug Interactions):  
x Primary Endpoints:  
x Comparison of the area under the plasma concentration-time curve (AUC) and 
Cmax of citalopram when administered alone  versus when co-administered with 
CBD after 7 days of CBD dosing 
x Comparison of the morphine AUC and C max when administered alone versus 
when co-administered with the first dose of CBD and after 7 days of CBD 
dosing   
x Secondary Endpoints:  
x Comparison of the AUC and C max of morphine metabolites when administered 
alone versus when co-administered with CBD  
x Exploratory Endpoints:  
x Additional PK parameters for citalopram, morphine, CBD, and metabolites, such 
as time of maximum concentr ation, half-life, apparent clearance, and apparent 
volume of distribution  
x PK parameters for CBD and metabolites  
Study Design:  
This is a two-part study. Part 1 is a randomi zed, double-blind, placebo- controlled, parallel study 
in 200 subjects (150 subjects receiving 5 mg/ kg/day of CBD and 50 subjects receiving 
placebo). Part 2 is an open-labe l, sequential study in 40 subjects (two separate cohorts of 20 
subjects).  
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 10 of 72 
  
 In Part 1, subjects will report to the study site fo r screening from Days -28 to -2 and then will 
return to the site on Day -1 for check-in, ba seline assessments, and ra ndomization. Subjects will 
check out from the clinical site on Day 1 (1  night in-house stay) following dosing and study 
assessments. Subjects will recei ve CBD or placebo for 28 days and will return to the study 
clinic on Day 28 for a single in-house day with ch eck-out on Day 29. Subjects  will have 3 clinic 
visits in between the in-house stays. The clini cal site will contact subjects daily to  remind 
subjects regarding their requireme nts for drug administration. Subject will have a final follow-
up on Day 35. 
In the Part 2 citalopram drug-dr ug interaction (DDI) cohort, subjec ts will report to the study site 
for screening from Days -28 to -2 and then will return to the site on Day -1 for check-in and baseline assessments. Subjects will check-out from the clinical site on Day 6 (6 nights in-house 
stay) following dosing and study assessments. Subj ects will return to the study clinic on Day 12 
for another 6 nights in-house stay with check -out on Day 18. Subjects will have one follow-up 
visit after the second check-out (Day 24). Subject s will receive CBD for 12 days (Day 6 to 17) 
and citalopram on Day 1 and Day 13. 
In the Part 2 morphine DDI cohort, subjects will report to the study site for screening from 
Days -28 to -2 and then will return to the site on Day -1 for check-in and baseline assessments. Subjects will check-out from the clinical s ite on Day 6 (6 nights in-house stay) following 
dosing and study assessments. Subjects will return  to the study clinic on Day 10 for a 3 night 
in-house stay with check-out on Day 13. Subjects will receive CBD for 9 days (Day 4 to 12) 
and morphine on Day 1, Day 4, and Day 11.  Subj ects will have one follow-up visit after the 
second check-out (Day 19).  
In both parts, the clinical site will contact the subjects daily on outpatient days to remind drug 
administration. Subjects will unde rgo assessments as describe d in the Study Summary and 
Schedule of Events (Appendix A: Schedule of Events Part 1 and Appendix B: Schedule of 
Events Part 2). 
Subject Population:  
Approximately 240 healthy subjects are planned for enrollment.  
Recruitment materials (e.g., inte rnet, radio, and print advertisem ents, social media posts) will 
be approved by the local Ins titutional Review Board (IRB, i. e., Advarra) before telephone 
screening. Subjects will be offered payment for Screening and participation in the study, but no 
special incentives are offered. 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 11 of 72 
  
 Study Drugs, Dosage, and Route of Administration:   
x Cannabidiol (Epidiolex) oral solution w ill be administered to  approximately 190 
participants (150 in Part 1 and 40 in Part 2). Dosing is 5 mg/kg/day administered in 
divided doses twice daily (i .e. 2.5 mg/kg twice daily).  
x Oral placebo solution (matching characteris tics of cannabidiol solution). Placebo will be 
administered twice daily to approximately 50 participants in Part 1.  
x DDI substrate drugs: oral morphine (15 mg ) and oral citalopram (20 mg). Of the 
participants in Part 2, 20 will receive morphine and 20 will receive citalopram. 
For Part 1, subjects will be administered CBD on Day 1 and provided with adequate drug for 
at-home dosing on Days 2 through 6 at check-out . At the clinic visit on Day 7, subjects will 
receive dosing for the day as well as at-hom e dosing for Days 8 through 13. This will be 
repeated for clinic visits on Day 14 (primary study drug to cover dosing on Days 15 through 20) 
and Day 21 (primary study drug to cover dosing on Days 22 thr ough 27). Subjects will continue 
to receive CBD twice daily after returning for check-in on Day 28 (last dose in the evening of Day 28).   
For Part 2, subjects in the citalopram cohort w ill be administered CBD on Day 6 and subjects in 
the morphine cohort will be ad ministered CBD on Day 4. Both Pa rt 2 cohorts will be provided 
with adequate drug for at-home dosing at check-out. Subjects will continue to receive CBD twice daily after returning for check-in on Day 12 (citalopram DDI cohort) and Day 10 
(morphine DDI cohort). The total number of days of CBD dosing will be 12 for the citalopram 
cohort and 9 for the morphine cohort.  Subject s will be administered the DDI substrate drug on 
Days 1 and 13 (citalopram DDI cohort) a nd Days 1, 4, and 11 (morphine DDI cohort).  
Key Inclusion Criteria:  
Subject is a healthy, non-smoking man or woman, 18 to 55 years of age, inclusive, who weighs 
at least 50 kg (110 lbs) and has a body mass index of 18.5 to 33.0 kg/m2, inclusive, at Screening 
and check-in.  Healthy to be defined as subj ect having no clinically significant findings from 
medical history, physical examin ation, 12–lead ECG, vital sign measurements, and clinical 
laboratory evaluations. 
Key Exclusion Criteria:  
Subjects will be excluded from this study if they have: 
1) Abnormal liver labs at screening or check-i n (Day-1), defined as any of the following 
(tests may be repeated once for conf irmation at screening and check-in):  
a) Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 
1.5 × ULN. (The ULN for ALT will be 33 U/L for males and 25 U/L for females) 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 12 of 72 
  
 b) Total bilirubin (TBL) > ULN 
c) International normalized ratio (INR) > 1.3  
2) Use or intend to use any medica tions/products in the 14 days prior to check-in (Day -1), 
unless deemed acceptable by the investigator  
For a more detailed listing of inclusion/exclusi on criteria, refer to sections 4.2.1 and 4.2.2 of the 
protocol.  
Sample Collection  
Number of samples collected throughout the study can be found in the Schedule of Events (see 
Appendices A and B). Unscheduled pharmacokinetic and proteomics samples will be collected in subjects from Part 1 who discontinue due to liv er enzyme elevation as part of monitoring.   
Pharmacokinetic Assessments:  
The pharmacokinetic blood samples (6 mL each) will be collected into tubes containing 
K2EDTA, inverted several times to mix the blood with the anticoagulant, and placed in an ice 
bath. Within 30 minutes of collection, the sa mples will be centrifuged for 10 minutes, at 
3000 relative centrifugal force (RCF), at 4°C, by a study team member.  
The plasma will be separated using a disposable plastic pipette and approximately half of the 
plasma will be transferred into duplicate cryot ube vials labeled as A liquot A (primary) and 
Aliquot B (backup). The plasma sa mples will be appropr iately labeled and stored frozen at –
70°C or below within 30 minutes after aliquoting until shipment. Temperature monitoring logs should be maintained and accessible for review by the study monitor.  
The Aliquot A samples (primary ) will be shipped first, on dr y ice, to the bioanalytical 
laboratory at FDA for processing when reque sted by the sponsor. The Aliquot B samples 
(backup) will be held for a second shipment after completion of a ll Aliquot A sample 
shipment(s) and the timing of the Aliquot B sh ipment will be communicated by the sponsor. 
Pharmacokinetic blood samples w ill be collected by direct venipuncture or by inserting an 
intravenous (IV) catheter on the following days. 
For Part 1, a single blood sample will be collected on days 1, 7, 14, 21, 29, and 35. Total 
number of PK blood samples will be  6 per subject for Part 1. 
For the Part 2 (citalopram DDI cohort), 13 PK sample s will be obtained with each citalopram 
dose. Total number of PK blood sa mples will be 26 per subject fo r Part 2 (citalopram cohort). 
For the Part 2 (morphine DDI cohort), 13 PK samples will be obtaine d with each morphine 
dose. Total number of PK blood samples will be 39 per subject for Part 2 (morphine cohort). 
For detailed timing of PK sampling, refer to 4.7.1.1 Pharmacokinetic Sa mple Collection.   
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 13 of 72 
  
 Additional Laboratory Assessments (Part 1):  
For Part 1, blood samples for assessment of ch anges from baseline in different endocrine, 
lipids, and plasma proteins will be collected on Day 1 (morning, prior to dosing) and at check-
out on Day 29 (morning, time-matched to  the initial pre-dose assessment). 
Blood samples will be collected by direct venipunc ture or by inserting an intravenous (IV) 
catheter. Using red top tubes (no additives), ap proximately 8-10 mL of blood will be collected 
and processed for analysis. Additional details fo r sample collection and sample processing are 
in Section 4.7.2 to 4.7.4. 
Safety Assessments:  
Safety will be evaluated in terms of adverse events (AEs), clinical laboratory results 
(hematology, serum chemistry, and urinalysis), v ital sign measurements (blood pressure, heart 
rate, respiratory rate, and oral body temper ature), safety 12-lead ECG, and physical 
examination findings.  
Sample Size Determination:  
Approximately 190 healthy partic ipants planned for enrollment will be administered CBD. For 
Part 1, the primary endpoint is the percentage of CBD administe red participants with an ALT 
(based on consensus criteria*) or AST liver enzyme elevation greater than three times the ULN.  
Assuming the true event rate is 6%, the st udy has 95% probability of  observing 5 or more 
events with ALT or AST liver enzyme elevation greater than three times the ULN. Assuming the true observed drug-induced liver injury (DILI)  event rate is 2%, the study has a 93% percent 
probability of observing 1 or more event. 
In Part 1, change from baseline comparisons will be performed for various  endocrine measures 
(e.g., total testoster one, inhibin B, TSH, total T3, and free T4). Sample size for the study is not 
powered for any of these comparisons nor are any adjustments planned for multiplicity.  
In Part 2, comparisons will be performed on ch anges in exposure for two different substrate 
drugs following administration with CBD. Assu ming no more than 20% discontinuations per 
arm, 30% intra-subject variability, and a two- sided test at the 0.05 significance level, the 
sample size would have 90% power to detect a 30% increase in exposure when the substrate 
drugs are co-administered with CBD. 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 14 of 72 
  
 Statistical Methods: 
All data will be presented in data listings. Data from subjects excluded from an analysis 
population will be presented in th e data listings, but not included in the calculation of summary 
statistics. Demographic and baseline characteristics will be summarized overall and by treatment for all subjects. The number of subj ects who enroll in the study and the number and 
percentage of subjects who complete each assessment will be presented. The frequency and percentage of subjects who withdraw or discontinue from the study and the reason for 
withdrawal or discontinuation will be summarized. 
Descriptive statistics will be used to summarize demographic and baseline subject 
characteristics. For continuous variables, the mean, median, standard deviation (SD), minimum, 
and maximum values will be reported. For categorical (nominal) variables, the number and percentage of subjects (or observations) will be reported. 
Primary Analysis (Part 1): 
The primary endpoint is the percentage of subj ects with an ALT (based on consensus criteria) 
or AST liver enzyme elevation greater than three times the upper limit of normal (ULN). Results will be reported as percentage with a 95% confidence interval (CI).  
Secondary and Explorator y Analysis (Part 1): 
The secondary liver endpoint is the percentage of  participants with drug-induced liver injury (as 
defined by international consensus criteria). Analysis and reporting will be performed similar to the primary endpoint. Exploratory liver endpoints include the percen tage of participants with 
ALT or AST above different thres holds. Additional liver analysis details will be specified in the 
Statistical Analysis Plan (SAP). 
Endocrine endpoints will include the changes fro m baseline in serum to tal testoste rone and 
inhibin B in males after CBD administration compared to pl acebo. Change from baseline in 
thyroid stimulating hormone, total T3, and free T4 in both males and females after CBD administration compared to placebo will also be assessed.  
The percentage of subjects with either a bnormal testosterone (mal es only) or abnormal 
laboratory tests will also be reported. Results will be presented as point estimates with associated 95% CI.  
Additional details for secondary and exploratory analyses will be  specified in the Statistical 
Analysis Plan (SAP). 
Primary Analysis (Part 2): 
The primary analysis for Part 2 will be a comparison of the area under the plasma 
concentration-time curve (AUC) and C max of citalopram or morphi ne when administered alone 
versus when co-administered with CBD (for morphine, this will include with the first dose of 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 15 of 72 
  
 CBD and after 7 days of CBD dosing). Additional details will be specified in the Statistical 
Analysis Plan (SAP).  
Secondary and Explorator y Analysis (Part 2): 
For the secondary PK endpoints, AUC and C max for morphine metabolites (alone and when co-
administered with CBD) will be analyzed using the same approach as the primary PK endpoints. 
Additional exploratory PK parameters for citalopram, morphine, CBD, and metabolites, such as 
time of maximum concen tration, half-life, apparent clea rance, and apparent volume of 
distribution will be analyzed using noncompartme ntal methods based on actual sampling times. 
All parameters will be calculated using statistical software. Mean and individual concentration time profiles will be presented in graphs. 
Additional details will be specified in the Statistical Analysis Plan (SAP). Safety (Part 1 and Part 2): 
The safety population will include all subjects who receive at l east 1 dose of the study drug. All 
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). The incidence of AEs, organized by system organ clas s and preferred term, w ill be summarized with 
a focus on treatment-emergent AEs. Vital sign measurements will be summarized using descriptive statistics by time point. All values will be evaluated for clinically notable results. Data for additional safety pa rameters (e.g., physical examin ation findings) will be listed. 
Date of Protocol:  J March 19, 2024 
 
  
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 16 of 72 
  
 1. INTRODUCTION 
The cannabis plant contains bioactive compounds known as cannabinoids; delta-9 
tetrahydrocannabinol (THC) and can nabidiol (CBD) are the most pr evalent cannabinoids in most 
varieties of cannabis.1 The Agricultural Improvement Act (Farm Bill) of 2018 removed hemp, 
defined as cannabis and derivatives  of cannabis with extremely lo w concentrations of THC, from 
the definition of marijuana in the Controlled Substances Act.1 Following this, many CBD 
products have been made availa ble to consumers. However, he mp products remain subject to 
regulation under the Federal Food Drug & Cosmetic  Act, when applicable (e.g., as drugs, foods, 
dietary supplements, cosmetics, veterinary products) and the growing CBD products market 
raises various safety concerns, especially with long-term use.1 
Cannabidiol (CBD) is extracted fr om Cannabis sativa L. plants. Pure  CBD typically contains less 
than 0.1% (w/w) tetrahydrocannabinol (THC). CBD  is available as a prescription drug product 
for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or 
tuberous sclerosis complex.2 At labeled doses up to 25 mg/kg/ day, an increased risk of liver 
enzyme elevation has been observed.2,3 However, only limited evaluations of the risk of liver 
enzyme elevation of daily, lower dose CBD use are available.3,4 The potential for liver enzyme 
elevations with CBD doses in  unapproved consumer products hi ghlights a need for further 
research to quantify risks at these doses. In a ddition, CBD has the capacity to inhibit cytochrome 
P450 enzymes and uridine 5’-diphospho-glucuronos yltransferases, leading to potential drug-drug 
interactions with multiple common medications.2,5 The clinical significance of many of these 
interactions is also unclear. Fu rthermore, nonclinical studies ha ve suggested the potential for 
CBD to cause reproductive and endocrine effects.6-8 As such, additional high-quality clinical 
pharmacology studies are needed to furthe r characterize CBD's safety profile. 
This study will be divided into two parts.  
In Part 1, 200 healthy subjects will be randomized  to 5 mg/kg/day of CBD (150 subjects) or 
placebo (50 subjects) for 4 weeks with weekly laboratory assessments to characterize the percentage of participants with  liver enzyme elevation (primary  endpoint) or meeting withdrawal 
criteria for potential drug-induced liver injury  (secondary endpoint). Additional secondary 
endpoints include the change from baseline to after 4 weeks of daily CBD dosing for male 
reproductive (testosterone and inhibin B) and thyroid hormones (thyroi d stimulating hormone 
[TSH], triiodothryronine [T3] and thryroxine  [T4]) as secondary endpoints. Exploratory 
endpoints include additional characterization of  liver findings and other blood biomarkers. 
In Part 2, 40 healthy subjects will receive either oral citalopram (20 subjects) or morphine (20 
subjects) at baseline and then again after receiving CBD 5 mg/kg/day to characterize the effect of daily cannabidiol use on the plas ma concentration of citalopram  and morphine. Citalopram was 
selected because it is a common prescription me dication for depression and anxiety that is 
metabolized by CYP2C19 and CYP3A4,
9 which CBD inhibits.5 Morphine was selected because 
it is a common opioid analgesic that is metabolized by UGT2B7,10 which CBD inhibits.5 
 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 17 of 72 
  
 2. STUDY OBJECTIVES 
Part 1: 
To characterize the effects of daily cannabidiol use at a dose within the range of what consumers 
are taking as unapproved cannabi diol products on liver enzyme  elevations and endocrine 
measures.   
Part 2:  
To characterize the effects of daily cannabidiol use at a dose within the range of what consumers 
are taking as unapproved cannabidi ol products on drug interactions.  
3. ENDPOINTS  
3.1  Part 1 
Primary Endpoint: 
x Liver: Percentage of participants with an ALT (based on consensus criteria*) or 
AST liver enzyme elevation greater than  three times the upper limit of normal (> 
3 × ULN)  
Secondary Endpoint: 
x Percentage of participants meeting wit hdrawal criteria for potential drug-induced 
liver injury (DILI) 
x Change from baseline in total testosterone and inhibin B in male participants after 
CBD administration compared to placebo 
x Change from baseline in thyroid stimulating hormone (TSH), total T3, and free 
T4 after CBD administration compared to placebo  
Exploratory Endpoints: 
x Assessment of liver-related adverse events  
x Summary of CBD and metabolite pharmacokinetics 
x Proportion of subjects with  abnormal laboratory (e.g., liver, endocrine) tests  
x Changes in additional laboratory and plasma proteome assessments  
*Consensus criteria for ALT elevation: ULN for ALT will be 33 U/L for males and 25 U/L 
for females 
3.2  Part 2 (Drug-Drug Interactions) 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 18 of 72 
  
 Primary Endpoints: 
x Comparison of the area under the plasma concentration-time curve (AUC) and 
Cmax of citalopram when administered alone  versus when co-administered with 
CBD after 7 days of CBD dosing 
x Comparison of the morphine AUC and C max when administered alone versus 
when co-administered with the first dose of CBD and after 7 days of CBD dosing   
     Secondary Endpoints: 
x Comparison of the AUC and C max of morphine metabolites when administered 
alone versus when co-administered with CBD  
      Exploratory Endpoints: 
x Additional PK parameters for citalopram, morphine, and metabolites, such as time 
of maximum concentration, ha lf-life, apparent clearanc e, and apparent volume of 
distribution 
x PK parameters for CBD and metabolites 
4. INVESTIGATIONAL PLAN 
4.1 Study Design 
Part 1 
Part 1 is a randomized, double-blind, placebo-co ntrolled, parallel study in 200 subjects over a 
single treatment period of 28 days. Oral solution CBD at a dosage of 2.5 mg/kg twice a day, for a 
total of 5 mg/kg CBD daily, w ill be administered to the trea tment group of 150 subjects. The 
placebo control group will consist of 50 subjects.  Subjects will report to the study site for 
screening from Days -28 to -2 and then will return to the site on Day -1 for check-in and baseline assessments. Subjects will check- out from the clinical site on Day 1 (1-night in-house stay) 
following dosing and study assessments. Subjects will receive take-home doses of CBD or 
placebo for 28 days and will return to the study clinic on Day 28 for a single in-house day with 
check-out on Day 29. Subjects will have 3 clinic visits in be tween the in-house stays. The 
clinical site will have daily follow-ups with subjects during out-patient days  to remind subjects regarding their requirements for drug administr ation. Subjects will have one follow-up visit on 
Day 35. Chemistry and hematol ogy assessments will be performed on days -1, 1, 7, 14, 21, 28, 
29, and 35. Endocrine assessments will be performed on days 1 and 29.  
The study design is as follows: 
 CBD Dosing Days 1-28 (5mg/kg/day)   
U.S. FOOD AND DRUG ADMINISTRATION Protocol Number: SCR-016
(Version 3.0)
CONFIDENTIAL Page 19of 72Day -1
Day 1 Day 7 Day 14 Day 21 Day 28Day 29 Day 35
Check-in Check-out Clinic visit 
1 Clinic visit
2 Clinic visit 3 Check-in Check-out Follow-up visit
(Clinic visit 4)
Part 2
Part 2 is an open-label, sequen tial study in 40 subjects. This part  will consist of  two treatment 
cohorts, a citalopram DDI cohort and a morphine DDI cohort. Each  treatment cohort will consist 
of 20 subjects.  
In the citalopram DDI cohort, subjects will report to the study site for screening from Days -28 to 
-2 and then will return to the site on Day -1 for check-in and baseline assessments. Subjects will check-out from the clinical site on Day 6 (6 nights in-house stay) following dosing and study 
assessments. Subjects will return to the study clin ic on Day 12 for another 6 nights in-house stay 
with check-out on Day 18. Subjects will have one follow-up visit after the second check-out 
(Day 24). Subjects will receive CBD for 12 days (D ay 6 to 17) and citalopram on Day 1 and Day 
13. 
In the morphine DDI cohort, subjects will report to  the study site for screening from Days -28 to 
-2 and then will return to the site on Day -1 for check-in and baseline assessments. Subjects will check-out from the clinical site on Day 6 (6 nights in-house stay) following dosing and study 
assessments. Subjects will return to the study clin ic on Day 10 for a 3 night in-house stay with 
check-out on Day 13. Subjects will receive CBD for 9 days (Day 4 to 12) and morphine on Day 
1, Day 4, and Day 11.  Subjects will have one foll ow-up visit after the second check-out (Day 
19). 
In both parts, the clinical site will have daily follow-ups after the first check-out visit subjects 
return for the second check-in vis it to remind drug administration.   

U.S. FOOD AND DRUG ADMINISTRATION Protocol Number: SCR-016
(Version 3.0)
CONFIDENTIAL Page 20of 72The study design is as follows:
Citalopram DDI cohort 
Day -1 Day 1CBD Dosing Days 6-17 (5 mg/kg/day)
Day 18 Day 24
Day 6 Day 12 Day 13
Check-in DDI drug Dosing
(baseline)Check-out Check-in DDI drug Dosing
(w/ CBD)Check-out Follow-up 
visit
Morphine DDI cohort
Day -1 Day 1CBD Dosing Days 4-12 (5 mg/kg/day)
Day 13 Day 19
Day 4 Day 6 Day 10 Day 11
Check-in DDI drug Dosing
(baseline)DDI drug Dosing
(w/ CBD)Check-
outCheck-
inDDI drug Dosing
(w/ CBD)Check-
outFollow-up visit

U.S. FOOD AND DRUG ADMINISTRATION Protocol Number: SCR-016
(Version 3.0)
CONFIDENTIAL Page 21of 72Parts 1 and 2 
During the screening visit (Days -28 to -2 for both Part 1 and Part 2), the inclusion and exclusion 
criteria will be reviewed to ensure the subject is appropriate for the study. The informed consent 
form will be reviewed with the subject by a me mber of the study team and the subject will be 
encouraged to ask questions to ensure he or she has a good understanding of the study. If the 
subject is eligible and agrees to participate, the subject will be asked to sign the informed consent form before any study-specific procedur e is performed, including randomization. 
After the consent process is complete, demographic data, medical history, and concomitant 
medications will be recorded. A physical ex amination will be performed by a study team 
member. Clinical laboratory tests (hematol ogy, serum chemistry, and urinalysis) will be 
performed. Female subjects must have a negative pregnancy test result. Screening tests will be performed within 28 days of and no later than 1 day before Day –1 for both parts. Subjects will undergo assessments as describe d above and in the Study Summa ry and Schedule of Events 
(Appendix A & B).
Subjects will be discharged from the study after completion of all study procedures. If a subject 
discontinues from the study premat urely, all procedures scheduled  for the end of the study will 
be performed. Meal timing and co mponents, activity levels, and general conditions in the study 
clinic will be as similar as possible on the treatment days. Subjects previously screened, but not initially enrolled in a cohort w ill be allowed to rescreen.
4.1.1. Risk/BenefitSubjects will be informed that participation in a human clinical pharmacology study like the 
present one cannot be of benef it to healthy volunteers. Nevertheless, the information from the 
physical examination, vital sign measurements, and laboratory test results may be shared with 
the subject’s personal physician if this is the subj ect’s choice. Subjects will be informed that it is 
also their choice to inform their personal physician that they are participating in this research 
study. 

U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 22 of 72 
  
 Subjects will be informed that th eir contribution to the study is of  major importance to agencies 
like the FDA to understand the effects of CBD on  liver safety, endocrine measures, and drug-
drug interactions.  However, since this is a study involving healthy volunteers, subjects will be 
informed that they have the option not to participate. 
Subjects will be informed that they may be expos ed to risks associated with the pharmacological 
properties of the study drug and the study proced ures. The following summary of potential AEs 
for the study drugs will be provided to and discussed with the subjects.  
1. Oral cannabidiol 5 mg/kg/day: The most common adverse events include somnolence, 
decreased appetite, diarrhea, ALT/AST elevation, fatigue, malaise, asthenia, rash, insomnia/sleep disorder, and infection.
2  
2. Oral citalopram 20 mg: The most common adverse events include fever, arthralgia, myalgia, 
anorexia, agitation, somnolence , insomnia, sinusitis, ejaculation disorder (primarily 
ejaculatory delay), decreased libido, and impotence.11  
3. Oral morphine 15 mg: The most common adve rse events include constipation, nausea, 
sleepiness, lightheadedness, dizzine ss, drowsiness, vomiting, and sweating.12  
Selected doses of individu al drugs are within the FDA approved labeled doses. 
x Cannabidiol – Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg BID for a 
total of 5 mg/kg/day for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days 
(citalopram cohort) in Part 2. Labeled dosing initiates treatment at 5 mg/kg/day. Dosing is capped at 25 mg/kg/day for maximum mainte nance dosage. DDI interactions can occur 
with drugs that are strong inducers/inhibitors  of CYP3A4 or CYP2C19 and substrates of 
UGT1A9, UGT2B7, CYP2C8, CYP2C9, and CYP2 C19. Studies with cannabidiol have 
initiated dosing at up to 25 mg/kg/day for 26 weeks
13, which is higher dosing and for a 
longer duration than proposed for this study. 
x Citalopram – Citalopram (Cel exa) will be administered once at 20 mg on days 1 and 13. 
Citalopram’s initial dosage is 20 mg once daily  with or without food and may increase to 
a maximum of 40 mg once daily.11 DDI interaction included CYP2C19 inhibitor. The 
maximum recommended dose of citalopram is 20 mg/day for patients who are taking 
concomitant CYP2C19 inhibitor since it may lead  to increased blood levels of citalopram 
and risk of QT prolongation or Torsade de Pointes.14 
x Morphine – Morphine will be  administered once at 15 mg on days 1, 4, and 11, which is 
within the range of labeled dosing. The initial dosage of morphine sulfate tablet is 15-30 
mg every 4 hours as needed, but due to the risk of addiction, abuse, and misuse with 
opioids, it is recommended to use the lowest effective dosage for the shortest duration.12  
The study drugs will not be administered to anyon e who is pregnant. A ll women must take a 
pregnancy test before receivi ng any study drug in this study. All women of childbearing potential 
enrolled on this study will be informed that th ey must use effective birth control methods 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 23 of 72 
  
 (abstinence, intrauterine device, and contra ceptive foam and a condom [i.e., double-barrier 
method]) during treatment. Subjects will be informed that they must notify the investigator if they or their female partners become pregna nt during the study. If a subject becomes pregnant, 
she will be informed that neither Spaulding Clini cal Research nor the sponsor will be responsible 
for the cost of any obstetric or related care, or for the child’s care. Female subjects will also be informed of the importance of not becoming pr egnant for 30 days following last medication 
dose. Male subjects will be informed of the importance of not fathering a child or donating 
sperm for 3 months following the last dose. 
Subjects will be informed that insertion of an  IV catheter may be required for blood sample 
collection and, during insertion of the catheter, so reness, bruising, or infection at the insertion 
site are possible but unlikely. Subjects will also be informed that dizziness and lightheadedness may occur during direct venipunctu re, insertion of the IV catheter, or during blood collection. 
Subjects will be informed that the confidentiality of their data will be respected at all times 
according to state law, and the study pe rsonnel handling their study data are bound by 
confidentiality agreements. 
Subjects will be informed that they may eat only meals and snacks that are provided during 
periods of their stay in the study clinic, and that th ey must consume each meal  that is served at a 
reasonable pace (within 25 minutes). 
Subjects will be informed that extra precautio ns will be put in place, including required 
screening tests, that will limit the risk of C OVID-19. Precautions will be documented in a 
COVID-19 risk management plan. Subjects will be informed that despite the extra precautions there is still a risk of them contracting COVID-19. Any changes to the COVID-19 precautions (e.g., due to updated CDC recomme ndations or new testing b ecoming available) will be 
documented in the COVID-19 risk mitigation plan.  
Subjects will be informed that the study drug and a ll tests, procedures, a nd visits required by the 
study are provided at no cost to them. If subject s become ill or physically  injured because of 
participation in this study, they will be informed that costs of treatment will not be covered by the sponsor. 
4.2 Selection of Study Population 
Subjects will be screened, and the data collected will be reviewed by the principal investigator. Only those subjects who meet all the eligibility criteria will be enrolled. Approximately 240 healthy subjects are planned for enrollment of which approximately  190 subjects will be 
administered CBD in parts 1 and 2. The DDI s ubstrate drugs of oral morphine and oral 
citalopram will be used in pa rt 2, with 20 subjects receiving mo rphine and 20 subjects receiving 
citalopram as per the schedule of events.  
4.2.1 Inclusion Criteria 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 24 of 72 
  
 Subjects who meet all the following inclusion criteria will be eligible  to participate in the study:  
1. Subject signs an IRB approved written informed consent and privacy language as per 
national regulations (e.g., Health Insurance Portability and Accountability Act 
authorization) before any study re lated procedures are performed.  
2. Subject is a healthy, non-smoking man or woma n, 18 to 55 years of age, inclusive, who 
weighs at least 50 kg (110 lbs) and has a body mass index of 18.5 to 33.0 kg/m2, inclusive, 
at Screening and check-in (Day -1). 
3. Subject has normal medical history findings , clinical laboratory results, vital sign 
measurements, 12-lead ECG results, and physical  examination findings at screening or, if 
abnormal, the abnormality is not considered clinically si gnificant (as determined and 
documented by the inves tigator or designee). 
4. Subject must have a negative test result for alcohol and illicit drugs at  screening and check-
in (Day -1).  
5. Participants must agree to refrain from usi ng any of the following for the duration of the 
study: alcohol, nicotine contai ning products, marijuana or marijuana-derived products, 
hemp or hemp-derived products, including CBD (except for provided study drug), and 
illicit drugs of any kind. 
6. Subject must test negative for severe acute  respiratory syndrome corona virus 2 (SARS-
CoV-2) by a rapid antigen test at check-in fo r all study periods. If a subject’s test comes 
back as invalid, the test can be repeated. 
7. Female subjects must be of  non-childbearing potential (non-ch ildbearing potential includes 
post-menopausal females de fined as spontaneous amenorrhea for at least 12 months with 
FSH in the post-menopausal range  and females who have under gone a hysterectomy) or, if 
they are of childbearing potential, they must: 1) have negative serum HCG at screening and 
check-in 2) have been strictly abstinent for 1 month before check-in (Day -1) and agree to 
remain strictly abstinent for the duration of th e study and for at least 1 month after the last 
application of study drug; OR 3)  be practicing 2 highly effec tive methods of birth control 
(as determined by the investig ator or designee; one of th e methods must be a barrier 
technique) from Screening until at least 1 month after the end of the study.   
8. Male subjects must agree to practice 2 highl y effective methods of birth control (as 
determined by the investigator or designee) beginning at check-in (Day -1) until at least 3 months after the last dose of study drug. Male  subjects may not donate sperm for 90 days 
after the end of the study.  
9. Subject agrees to and is highly likely (as determined by the investigator) to comply with the 
protocol defined procedures  and to complete the study. 
4.2.2 Exclusion Criteria 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 25 of 72 
  
 Subjects who meet any of the following exclusion criteria will not be eligible to participate in the 
study:  
1. Abnormal liver labs at screening on check-in (Day –1), defined as any of the following 
(tests may be repeated once for conf irmation at screening and check-in):  
a. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 
× ULN. (The ULN for ALT will be 33 U/L for males and 25 U/L for females.) 
b. Total bilirubin (TBL) > ULN.  
c. International normalized ratio (INR) > 1.3  
2. Use or intend to use any medica tions/products in the 14 days prior to check-in (Day -1), 
unless deemed acceptable by the investigator  
3. Subject is currently participa ting in another clinical study of  an investigational drug or 
has been treated with any investigational drug within 30 days or 5 half-lives (whichever 
is longer) of dosing for this study.  
4. Subject has used nicotine-containing products (e.g., cigarettes, cigars, chewing tobacco, 
snuff, electronic cigarettes) within 6 week s of Screening. Subjects must refrain from 
using these throughout the study. 
5. Subject has consumed alcohol, xanthine-containing products (e .g., tea, coffee, chocolate, 
cola), caffeine, kava melatonin, St Johns War t, grapefruit, or grapefruit juice within 
24 hours of check-in. Subjects must refrain  from ingesting these throughout the study.  
6. Subject is unable to tolerate a controlle d, quiet study conduct environment, including 
avoidance of music, television, movies, games, and activities that may cause excitement, emotional tension, or arousal during the pres pecified time points (e.g., before and during 
CBD dosing).  
7. Subject has a history of consuming more than  14 units of alcoholic beverages per week 
within 6 months before Screeni ng, has a history of alcoholism or 
drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12 ounces 
of beer, 4 ounces of wine, or 1 ounce of spirits/hard liquor). 
8. Subject has a positive test result for alc ohol or drugs of misuse (amphetamines, 
barbiturates, benzodiazepines, cocaine, al cohol, opiates, phenc yclidine, propoxyphene, 
and methadone) at Screening or Check-in (Day  -1 [both Parts]; Day 10 [morphine DDI]; 
Day 12 [citalopram DDI]). Subject has a positive test result for cannabinoids (THC) at screening or Day -1. 
9. Subject has a history of op ioid or narcotic misuse. 
10. Subject has a history of suicidal id eation or previous suicide attempts 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 26 of 72 
  
 11. Subject has a history or evidence of a clini cally significant disorder, condition, or disease 
(e.g., cancer, human immunodeficiency virus [HIV],  hepatic or renal impairment) that, in 
the opinion of the investigator, would pose a risk to subject safety or interfere with the 
study evaluation, procedures, or completion.   
12. Subject has a diagnosis of COVID-19 or any si gns or symptoms that are consistent with 
COVID-19 per CDC recommendations  at screening or check-in (Day -1). These include 
subjects with fever or chills, cough, shortne ss of breath or difficulty breathing, fatigue, 
muscle or body aches, headache, new loss of ta ste or smell, sore throat, congestion or 
runny nose, nausea or vomiting,  diarrhea, or other symptoms indicative of likely 
COVID-19 in the opinion of the investigator.  
13. Subject has known or suspected allergies or  sensitivities to the study drug or placebo 
components (e.g., sucralose, sesame).  
14. Subjects with a documented hypersen sitivity reaction to cannabidiol 
15. Subjects with a documented medi cal history of clinical diso rders related to mood, anxiety 
or panic, including diagnosed depression, generalized anxiety disorder or panic attacks. 
16. Subject has any condition possibly affec ting study drug absorption (e.g., gastrectomy, 
Crohn’s disease, irritable bowel syndrom e). Uncomplicated cholecystectomies and 
appendectomies may be included at the investigator’s discretion. 
17. Subject has clinical laborator y test results (hematology, serum chemistry and urinalysis) 
at Screening or Check-In that are outside the reference ranges provided by the clinical 
laboratory and considered clini cally significant by the investig ator. Tests may be repeated 
once for confirmation at both Screening and Check-In.   
18. Subject has a positive test result at Screen ing for HIV 1 or 2 antibody, hepatitis C virus 
antibodies, or hepatitis B surface antigen.  
19. Subject has a mean systolic blood pressure <85 or >145 mmHg or a mean diastolic blood 
pressure <45 or >95 mmHg at either Sc reening or Check-in. Blood pressure will be 
measured in triplicate after the subject has been resting in a supine position for a minimum of 5 minutes.  
20. Subject is unable or unwilling to under go multiple venipuncture s for blood sample 
collection because of poor tolerability or is  unlikely to complete the study due to poor 
venous access.  
21. Female subject is currently pregnant or lact ating or was within 3 months of the study.  
22. Subject has had any significant blood loss, dona ted 1 unit (450 mL) of blood or more, or 
received a transfusion of any blood or blood products within 60 days , or donated plasma 
within 7 days before Check-in. 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 27 of 72 
  
 23. Subject has any other condition that precludes his or her pa rticipation in the study (as 
determined by the investigator). 
4.3 Screening Failures 
Subjects who sign and date the informed consent form but who fail to meet the inclusion and 
exclusion criteria are defined as screening failures. A screening log, which documents the subject 
initials and reason(s) for screening failure, will be maintained by the investigator for all screening failures. A copy of the log should be  retained in the investigator’s study files. 
If a subject fails the screening process because of  an abnormal laboratory result, they can receive 
a copy of the results upon request. The investigat or will determine if fo llow-up for the abnormal 
laboratory result is needed and will encourage the subject to follow up with his or her personal physician as appropriate. All subj ects will be informed as to the reason(s) they are excluded from 
study participation, even if follo w-up is not required. If a subject fails the screening process 
because of a positive test result for human immunodeficiency virus or hepatitis, the positive 
result will be reported to local health authorities as required by law. 
4.4 Termination of Study or Investigational Site 
4.4.1 Criteria for Termination of the Study 
The study will be completed as planned unless one  of the following criteria is satisfied that 
requires early termination of the study. 
x New information regarding the safety or efficacy  of the study drug(s) that indicates a change 
in the known risk profile for the study drug(s), su ch that the risk is no longer acceptable for 
subjects participating in the study. 
x One or more serious adverse events (SAEs) th at are determined to be related to the study 
drug occur. SAEs are defined as events that result in death, are life-threatening, or require 
hospitalization.  
x Significant violation of Good Clin ical Practice (GCP) that compromises the ability to achieve 
the primary study objective or compromises subject safety. 
4.4.2 Criteria for Termination of  the Investigational Site 
The study site may be terminated if the site (i ncluding the investigator) is found in significant 
violation of GCP, the protocol, the contractual agreement, or is unable to ensure adequate 
performance of the study. 
In the event that the sponsor elects to termin ate the study or the investigational site, a study-
specific procedure for early termination will be  provided by the sponsor; the procedure will be 
followed by the applicable investigational site during the cour se of termination. 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 28 of 72 
  
 4.5 Criteria for Subject Withdrawal 
Subjects may withdraw from the study at any time  at their own request, or they may be 
withdrawn by the investigator without the approval  of the subject based on the investigator’s 
clinical judgment. A subject is  not required to provide a writte n request to withdraw from the 
study; however, a written request is required if a subject withdraws consent for his or her 
personal data to be used  for study related purposes. 
A subject may be discontinued for any of the following reasons: 
x AE: The subject has experienced an AE that, in  the opinion of the investigator, requires early 
termination. The appropriate electronic case repo rt form (eCRF) must be completed for each 
AE. If a subject is discontinued from the study due  to an AE, the investigator is required to 
follow up with the subject until the event resolves or becomes stable. If a subject dies during the study, the cause of death must be reported as  a serious AE (SAE), with an outcome of 
death noted in the eCRF. 
x Withdrawal Criteria for Potential Drug-Induced  Liver Injury (DILI): laboratory results 
meeting any of the following criteria. 
o ALT or AST > 3 x ULN (ULN for ALT is 33 U/L for males and 25 U/L for 
females) with the appearance of fatigue, nausea,  vomiting, right upper quadrant 
pain or tenderness, fever, ras h, and/or eosinophilia (> 5%) OR 
o $/7HOHYDWLRQî8/18/1IR U$/7LV8/IRUPDOHVDQG 8/IRU
females) OR 
o $/3HOHYDWLRQî8/1ZLWK DFFRPSDQ\LQJHOHYDWLRQVRI**7LQ WKHDEVHQFH
of known bone pathology driving the rise in ALP level) OR 
o $/7HOHYDWLRQî8/1DQGE LOLUXELQFRQFHQWUDWLRQ!î8/1  
When subject withdrawal occurs due to potentia l DILI, the study drug will be discontinued, and 
monitoring will still be continued to document subsequent liver test results and resolution of biochemical abnormalities. Wherever  possible, the investigator should arrange for the subject to 
return to the clinical site as soon as possibl e (within 24 hours of notice of abnormal results) for 
repeat assessment of laboratory results to confirm that the subject meets the trial discontinuation criteria as well as to obtain de tailed history and to  perform a physical examination. Subjects 
should be followed with frequent (every 24 to 48 hours) repeat clinical laboratory assessments 
and any other appropriate asse ssments until all abnor malities normalize (in the investigator’s 
opinion) or return to the baseline state. Th e subject will be discontinued from the study and 
returned to the study site for repeat and follow-up assessments. These follow-up steps are 
outlined in more detail in a separate procedures document. 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 29 of 72 
  
 x Protocol Violation: The subject failed to meet protocol entry criteria or did not adhere to 
protocol requirements, and con tinued participation poses an unne cessary risk to the subject’s 
health. 
x Withdrawal by Subject: The subj ect (or other responsible indi vidual [e.g., caregiver]) wishes 
to withdraw from the study in the absence of a medical need. 
NOTE: Withdrawal due to an AE should not be recorded in the “voluntary withdrawal” 
category. 
x Study Terminated by Sponsor: The sponsor, I RB, FDA, or other regulatory agency 
terminates the study. 
x Pregnancy: The subject is  found to be pregnant. 
NOTE: If the subject is found to be pregnant , the subject must be withdrawn immediately. 
The pregnancy will be followed up to term, and the outcome, including any premature termination will be recorded. All live births must be followed for a minimum of 30 days or until the first well-baby visit. 
x Other. 
NOTE: This category records withdrawals caused  by an accidental or  a medical emergency, 
unblinding, and other rare cases. The specific reason should be recorded in the comment 
space of the eCRF. 
4.5.1 Handling of Withdrawals The investigator may terminate a subject’s study participation at any time  during the study when 
the subject meets the criteria de scribed in Section 4.5. In additi on, a subject may discontinue his 
or her participation without giving a reason at any time during the study. Subjects will be 
informed that their participation in the study is voluntary, that refusal to participate will involve 
no penalty or loss of benefits to which the subject is otherwise entitled, and that the subject may discontinue participa tion at any time without pena lty or loss of benefits to which the subject is 
otherwise entitled. 
Should a subject’s participation be discontinued, the primary r eason for termination must be 
recorded. In addition, efforts should be made to perform all procedures scheduled for the early 
termination visit.  
4.5.2 Replacement of Subjects Approximately 240 healthy subjects are planne d for study enrollment with Part 1 having 150 
subjects randomized to CBD dosing and 50 subj ects to placebo control. Approximately 40 
healthy subjects are planned for enrollment in Pa rt 2 (20 subjects per DDI cohort). Replacement 
subjects may be assigned depending on discontinuations  during Part 1 and 2. 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 30 of 72 
  
 4.6 Study Visits 
4.6.1 Recruitment 
Recruitment materials (e.g., internet, radio, and pr int advertisements, social media posts) will be 
approved by the local IRB before telephone screening. The sponsor is  responsible for registration 
of the study on clinicaltrials.gov. R ecruitment may not occur until the study is fully registered on 
clinicaltrials.gov. 
4.6.2 Compensation 
Subjects will be offered payment for Screening; ho wever, if the results of their alcohol and drug 
screening tests are positive, they will not be compensated. Subjects who complete the entire study will receive payment according to the schedule  provided in the informed consent form. No 
special incentives are offered. Final payment will not be released until all follow-up procedures have been completed and acc epted by the investigator. 
If a subject chooses to withdraw from the study pr ematurely, he or she will only be compensated 
for completed days. If subjects are withdrawn for medical reasons or if the study is halted 
temporarily or permanently, the subjects will receive compensation pr oportional to the time 
spent in the study. No compensation will be provide d if a subject is dismissed from the study for 
noncompliance (e.g., improper conduct, ingesting al cohol and/or drugs [i ncluding recreational 
drugs], tampering with the study drug, consu ming any prohibited f oods or beverages). 
If subjects are required to stay in the clinic for a longer period for safety reasons, they will be 
compensated at a rate proporti onal to the entire compensation fo r the study. If a subject becomes 
ill or physically injured because of participation in this study, the subject will be referred for 
treatment. 
4.6.3 Screening  The following procedures and assessments will be performed at Screening for both parts (Days -
28 to –2): 
x Obtain informed consent/HIPAA authoriza tion. The informed consent process will be 
performed by a clinical research nurse in a private room. The subject will be given unlimited time to ask questions regardi ng study participation, and each subject will be questioned to 
ensure their understanding. 
After informed consent is obtained: 
x Review inclusion/exclusion criteria to confirm subject eligibility 
x Record demographic information 
x Measure height, weight, a nd calculate body mass index 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 31 of 72 
  
 x Perform serology screening (HIV antigen /antibody [Ag/Ab] Combo 1/2, HepC antibody, 
HBsAg) 
x Record medical history 
x Perform alcohol and drug scr eening (amphetamines, barbiturate s, benzodiazepines, cocaine, 
alcohol, opiates, phencyclidine, propoxyphene , cannabinoids (THC), and methadone) 
x Perform urine cotinine test 
x Perform a serum pregnancy test (female subjects only) 
x Perform FSH assessment (postmenopausal [i.e ., spontaneous amenorrhea for at least 12 
months] female subjects only)   
x Record prior medications 
x Monitor for AEs 
x Perform clinical laboratory tests (hem atology, serum chemistry, and urinalysis) 
x Measure vital signs (blood pressure, heart rate , respiratory rate, and oral body temperature) 
x Perform a safety 12 lead ECG 
x Perform a complete physical examination 
4.6.4 Study Periods 4.6.4.1 Check-In (Day -1) The following procedures and assessments will be performed at check-in (Day -1 for both parts): 
x Perform/review results from SARS-CoV-2 rapid antigen test  
x Review inclusion/exclusion criteria to confirm subject eligibility 
x Review medical history  
x Perform targeted physical examination 
x Weight measurement  
x Perform alcohol and drug screening (ampheta mines, barbiturates, benzodiazepines, cocaine, 
alcohol, opiates, phencyclidine, propoxyphene , cannabinoids (THC), and methadone) 
x Perform liver function tests (ALT, AST, GGT, ALP, PT/INR, TBili)    
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 32 of 72 
  
 x Perform urine cotinine test 
x Perform a serum pregnancy test (female subjects only) 
x Admit subject to the study clinic 
x Randomization (after completion of check-in pro cedures or just before dosing on Day 1 of 
each study period) (Only Part 1)  
x Record concomitant medications 
x Monitor for AEs 
x Perform clinical laboratory tests (hem atology, serum chemistry, and urinalysis) 
x Measure vital signs (blood pressure, heart rate , respiratory rate, and oral body temperature) 
x Perform a safety 12 lead ECG  
4.6.4.2 Treatment 
The following procedures and assessments will be  performed during the treatment period. Please 
refer to the Schedule of Events (Appendix A a nd B) for the specific days of assessments. 
x Monitor for AEs 
x Record concomitant medications 
x Administer study drug according to Schedule of  Events (Appendix A and B). Administration 
of study drug [Part 1: clinic visits and Da y 28, Part 2: Day 12 (citalopram) and Day 10 
(morphine)] can occur prior to review of safety labs. 
x Measure vital signs (blood pressure, heart rate , respiratory rate, and oral body temperature).  
x Perform targeted physical examinati on (at investigator’s discretion) 
x Collect PK blood samples (6 mL) at timepoint s specified in Section 4.7.1.1. Blood samples 
will be collected by direct venipuncture or by inserting an intravenous (IV) catheter. 
x Collect blood samples for laboratory tests.  
x Collect whole blood sample for pharm acogenetic testing (Only Part 2) 
 4.6.4.3 Discharge (or Early Termination) 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 33 of 72 
  
 The following procedures and assessments will be performed before a participant is discharged 
at the end of the study or at early termination: 
x Perform liver function tests (ALT, AST, GGT, ALP, PT/INR, TBili)    
x Record concomitant medications 
x Monitor for AEs 
x Measure height, weight, a nd calculate body mass index 
x Perform clinical laboratory tests (hem atology, serum chemistry, and urinalysis) 
x Measure vital signs (blood pressure, heart rate , respiratory rate, and oral body temperature) 
x Perform a serum pregnancy test (female subjects only) 
x Collect PK blood sample (6 mL)  
x Perform a safety 12-lead ECG  
x Perform a complete physical examination 
x Discharge subject from the study clinic af ter completion of all study procedures 
4.7 Study Procedures 
4.7.1 Pharmacokinetic Assessments 
4.7.1.1 Pharmacokinetic Sample Collection  
Pharmacokinetic blood samp les will be collected by direct ve nipuncture or by inserting an IV 
catheter. In Part 1, a single bl ood sample will be collected on Da y 1, Day 7 (clinic visit), Day 14 
(clinic visit), Day 21 (clinic vi sit), Day 29, and a final sample collection at follow-up on Day 35. 
Clinic visits may be completed outside of the listed visit day pe r investigator’s decision. Total 
number of PK blood samples will be  6 per subject for Part 1. Each  blood sample w ill be labeled 
with subject number, study number, study day, time poi nt, event, and a barcode that matches that 
belonging to the subject. All lab collections will take place predose and within 1 hour of 
mealtime.  
Part 1 PK collections: 
x Days 1, 7, 14, 21, 29, 35 
For Part 2, both the citalopram  and morphine DDI cohorts w ill have 13 PK sa mples obtained 
during each in-house stay. Total number of PK blood samples will be 26 per subject for the 
citalopram DDI cohort and 39 per subject for th e morphine DDI cohort. Each blood sample will 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 34 of 72 
  
 be labeled with subject number , study number, study day, time point , event, and a barcode that 
matches that belonging to the subject. 
Part 2 PK collections: 
x Citalopram DDI cohort 
o Days 1 and 13: 8 PK samples 
 0, 1, 2, 3, 4, 6, 8, 12 hours 
o Days 2 and 14: 1  
 24 hours 
o Days 3 and 15: 1 
 48 hours 
o Days 4 and 16: 1 
 72 hours 
o Days 5 and 17: 1 
 96 hours 
o Days 6 and 18: 1 
 120 hours  
x Morphine cohort 
o Days 1, 4 and 11: 11 PK samples 
 0, 15, 30, 45, 60, 90 minutes  
 2, 3, 4, 6, 12 hours 
o Days 2, 5 and 12: 1 
 24 hours 
o Days 3, 6 and 13: 1 
 48 hours 
4.7.1.2 Pharmacokinetic Specimen Handling 
The PK blood samples (6mL each) will be  collected into tubes containing K 2EDTA, inverted 
several times to mix the blood with  the anticoagulant, and placed in an ice bath. Within 30 
minutes of collection, the sample s will be centrifuged for 10 minutes, at 3000 RCF, at 4°C, by a 
study team member. 
The plasma will be separated using a disposable  plastic pipette and e qually aliquoted into 
duplicate cryotube vials labeled as Aliquot A (primary) and Aliquot B (backup). The plasma 
samples will be appropriately labeled and stored frozen at -70°C or below within 30 minutes after aliquoting until shipment. Temperature monitoring logs should be maintained and 
accessible for review by the study monitor.  
The Aliquot A samples (primary) w ill be shipped first, on dry ice, to the bioanalytical laboratory 
at FDA for processing when requested by the sp onsor. The Aliquot B sa mples (backup) will be 
held for a second shipment after completion of all Aliquot A sample sh ipment(s) and the timing 
of the Aliquot B shipment will be communicated  by the sponsor. None of the PK blood samples 
will be stored at the clinical facility for future use. 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 35 of 72 
  
 4.7.1.3 Pharmacokinetic Parameters 
The following PK parameters will be determined for Part 2 which will include citalopram and 
morphine with or without CBD.  
x Maximum observed plasma concentration (C max) 
x Area under the plasma concentration time curve (AUC) 
x Time at which C max occurs (T max) 
x Elimination rate constant (K el) 
x Terminal half-life (t 1/2)  
4.7.2 Endocrine Assessments Endocrine assessments will be collected in Part  1 on the study days outlined below to determine 
total testosterone and in hibin B for males, and t hyroid panel with TSH valu es for all participants. 
Blood samples will be collected by direct venipunc ture or by inserting an intravenous (IV) 
catheter. Using red top tubes (no additives), approximately 8-10 mL of  blood samples will be 
collected to provide sufficient serum for all sche duled assays—total testos terone, inhibin B, and 
thyroid function (TSH, total T3, free T4).  
For Part 1, blood samples for endoc rine assessment will be collect ed on Day 1 (morning, prior to 
dosing) and at check-out on Day 29 (morning, time-m atched to the initial pre-dose assessment).  
4.7.2 Lipid Assessments For the lipid assessment, approx imately 5 mL of whole blood will be collected and processed for 
serum. Blood samples will be collected by direct  venipuncture or by inserting an intravenous 
(IV) catheter. Samples will be collected into red top tubes (no additives).  
For Part 1, blood samples for lipid assessments will be collected on Day 1 (morning, prior to 
dosing) and at check-out on Day 29 (morning, time -matched to the initial pre-dose assessment). 
Lipid assessments will include total cholesterol, LDL, HDL, and triglycerides. 
4.7.2 Proteomics Assessments For the proteomics assessments, approximately 5 mL of whole- blood samples will be collected 
and processed for plasma. Whole blood should be  collected in BD Vacutainer® Venous Blood 
Collection Tubes containing EDTA (or any ot her primary blood collection tube containing 
EDTA as anticoagulant) and stored at room temperature (15–25°C) or 4°C before processing 
within 1 hour. Heparin-containing blood collection t ubes should not be used as this anticoagulant 
can interfere with downstream analyses.  
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 36 of 72 
  
 Plasma samples should be proces sed, aliquoted (approximately 700 μL volumes), and placed 
into the -80C freezer within 2 hours of collection.  
For Part 1, blood samples for proteomics assessmen ts will be collected on Day 1 (morning, prior 
to dosing) and at check-out on Day 29 (m orning, time-matched to the initial pre-dose 
assessment).  
4.7.3 Safety Assessments 
Safety will be evaluated in terms of AEs, clinical labor atory results (hematology, serum 
chemistry, and urinalysis), vital sign measurements  (blood pressure, heart rate, respiratory rate, 
and oral body temperature), safety 12 lead EC G results, and physical examination findings.  
4.7.3.1 Adverse Events 
4.7.3.1.1 Adverse Event Definitions 
An AE is defined as any untoward and/or unintended sign, including an abnormal clinical 
laboratory finding, symptom, or disease tempora lly associated with the use of a study drug, 
whether or not considered rela ted to the study drug. Events or conditions that increase in 
frequency or severity during or as a consequence of use of a drug in human clinical trials will also be considered AEs. 
A treatment emergent adverse event (TEAE) is defined as an AE that begins after study drug 
administration. 
An unexpected AE is any AE having a specificity or severity not consis tent with the current 
investigator’s brochure for the study drug(s). 
A serious adverse event (SAE) is defined as any AE occurring at any dose that meets the 
following criteria: 
x Results in death, 
x Is life threatening, 
x Requires hospitalization or prolongation of ex isting hospitalization, 
x Results in persistent or significant disability or incapacity, 
x Results in a congenital anomaly/ birth defect due to exposure prior to conception or during 
pregnancy, or 
x Is an important medical event that may not  meet the previous criteria but, based upon 
appropriate medical judgment, jeopardizes the subject or re quires medical or surgical 
intervention to prevent one of the outcomes listed previously. 
4.7.3.1.2 Adverse Event Reporting 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 37 of 72 
  
 The recording of AEs will begin after the subject signs the informed consent form and will 
continue until discharge (or early  termination). All AEs, whet her serious or nonserious and 
whether or not related to the study drug, must be  recorded in the eCRF. Study subjects will be 
instructed to warn study staff if he or she has any unexpected symptoms. In addition, all subjects 
will receive a reminder telephone call approximately 24 h before check-in. 
Any SAE (whether expected or unexpected) must be entered into the e CRF system and reported 
by email to the medical monitor or designee us ing the SAE Reporting Form within 24 h of the 
investigator or study clinic staff becoming aware of the event. It is the responsibility of the 
investigator to report all SAEs to the medical monitor, to provide the most complete report possible, and to assess each SAE for its rela tionship to the study drug. The investigator is 
responsible for obtaining follow-up information on all SAEs and sub mitting follow-up SAE data. 
Any unexpected SAEs must be reported promptly to the investigator’s IRB as per the IRB’s 
requirements. 
In the event of a fatal or life-threatening SA E, the sponsor will notif y the appropriate FDA 
authorities within 7 calendar days of receipt of the report. The s ponsor will follow all 7 day alert 
reports with a written report within 10 working days of receipt of the case. Serious AE cases that concern nonfatal, non-life-threatening events that are unexpected and at least possibly related to 
the study drug will be submitted in writing to th e FDA within 10 working days of receipt. 
Furthermore, any AEs that are not expected, occur at a higher frequency, or would require 
modification of the study protocol and/or informed consent must be reported to the FDA within 
10 working days. 
Adverse events that are assessed by the investig ator as possibly or proba bly related to the study 
drug will be followed until they resolve or stab ilize. All SAEs will be followed until resolution. 
4.7.3.1.3 Assessment of Severity 
The investigator will assess the severity of each AE using the following scale: 
x Mild: The subject is aware of the AE but is still able to perform all activities; minimal or no 
medical intervention or therapy is required. 
x Moderate: The subject has to discontinue some activities due to the AE; minimal or no 
medical intervention or therapy is required. 
x Severe: The subject is incapacitated by the AE and is unable to perform normal activities; 
significant medical intervention or therapy is  required, and hospitalization is possible. 
4.7.3.1.4 Assessment of Causality 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 38 of 72 
  
 The investigator will assess th e causal relationship/ relatedness of each AE to the study drug 
using the following scale: 
x Not Related: Onset of the AE has no reasonable temporal rela tionship to administration of 
the study drug, a causal relationship to adminis tration of the study drug is biologically 
implausible, or the event is attri buted to an alternative etiology. 
x Unlikely Related: Onset of the AE has a re asonable temporal relationship to study drug 
administration and although a causa l relationship is unlikely, it is biologically plausible. 
x Possibly Related: Onset of the AE has a strong temporal relati onship to administration of the 
study drug, cannot be explained by the subject’s clin ical state or other f actors, and a causal 
relationship is biologically plausible. 
x Probably Related: On set of the AE shows a distinct tempor al relationship to administration of 
the study drug that cannot be explained by the subject ’s clinical state or other factors, the AE 
is a known reaction to the product or chemical  group or can be predicted by the product’s 
pharmacology. 
4.7.3.1.5 Pregnancy 
A serum pregnancy test will be performed for female subjects at the time points presented in the Schedule of Events (Appendix A and B). If a s ubject becomes pregnant while on the study, this 
should be reported immediately to the investigator , the subject will be withdrawn from the study 
and the medical monitor and the subject will be instructed to follow up with his or her personal physician. All pregnancie s are to be reported as an AE and followed for outcome. 
4.7.3.2 Clinical Laboratory Tests Clinical laboratory and diagnostic screening tests will be performed  at the time points presented 
in the Schedule of Events and will be collected in accordance with acceptable laboratory procedures. Clinical laboratory testing will be pe rformed by the clinical study contractor(s). The 
clinical laboratory tests that will be performed are presented in Table 4-1. Unused clinical laboratory test samples will not be stored for future use. 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 39 of 72 
  
 Table 4--1: Clinical Laboratory Tests & Diagnostic Screening Tests 
Hematology Serum Chemistry Urinalysis 
Hematocrit 
Hemoglobin Platelet count 
Red blood cell count White blood cell count (with 
automated differential) Alanine aminotransferase 
Albumin Alkaline phosphatase 
Aspartate aminotransferase Bicarbonate Bilirubin (total, direct, and indirect) 
Blood urea nitrogen 
Calcium Chloride Creatinine (including calculated creatinine clearance by CKD-EPI) 
Gamma-glutamyl transferase 
Glucose Lactate dehydrogenase Magnesium Phosphorus Potassium Sodium Total protein 
Uric acid 
 
Specific laboratory tests (Part 1): 
Total and free testosterone 
Inhibin B Thyroid stimulating hormone Triiodothyronine (total T3) Thyroxine (free T4) 
Lipid Panel  
Additional assessments in subjects for 
liver enzyme monitoring: 
 
International normalized ratio (INR) 
Prothrombin time Appearance 
Bilirubin Blood 
Color Glucose Ketones 
Leukocyte esterase 
Microscopic examination: red blood cells, white blood cells, epithelial cells, bacteria, crystals, and casts (if present) Nitrite pH Protein Specific gravity Urobilinogen 
Diagnostic Screening Tests:  
Serum  Urine  Whole Blood 
Serology (human 
immunodeficiency virus 
Ag/Ab Combo 1/2, hepatitis C 
virus antibody, and hepatitis B 
surface antigen) 
Female Subjects Only 
Human chorionic gonadotropin (for pregnancy) 
Follicle-stimulatin
g hormone Drug screen includ ing amphetamines, 
barbiturates, benzodiazepines, cocaine, 
alcohol, cannabinoids (THC) 
(excluded for Day 28 check-in, Part 1), 
opiates, phencyclidine, propoxyphene, methadone, and cotinine 
  Pharmacogenetic testing may be performed 
(CYP2C19, Day-1 Part 2 citalopram cohort; 
UGT2B7, Day -1 and Part 2 morphine cohort). Additional details will be provided in a separate laboratory document.
 
Other 
SARS-CoV2 rapid antigen test  
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 40 of 72 
  
 Clinical laboratory results will be reviewed by the investigator or designee together with data in 
the eCRF. Any values outside the reference range will be evaluated for clinical significance. If a value is determined to be clinically significant, the subject will be instructed to follow up with his or her personal physician. Th e investigator or designee may repeat the clinical laboratory 
tests if deemed appropriate. The investigator w ill maintain a copy of th e laboratory accreditation 
and the reference ranges for the laboratory used. 
4.7.3.2.1  Assessment and Reporting of Potential Cases of Drug-Induced Liver Injury 
The investigational site is requi red to submit to the sponsor the laboratory results for any subject 
after admission to the study that meets one of the following criteria:  
x ALT or AST > 3 x ULN (ULN for ALT is 33 U/L for males and 25 U/L for females) 
with the appearance of fatigue, nausea, vo miting, right upper quadrant pain or tenderness, 
fever, rash, and/or eosinophilia (> 5%) 
OR 
x ALT elevation î8/18/1IRU$/7 is 33 U/L for males and 25 U/L for females)  
OR 
x ALP elevation î8/1 (with accompanying elevations of GGT in the absence of 
known bone pathology driving th e rise in ALP level)  
OR 
x ALT elevation î8/1DQG bilirubin concentration > 2 × ULN 
When subject withdrawal occurs due to pot ential Drug-Induced Liver Injury (DILI), the 
study drug will be discontinue d, and monitoring will still be continued to document 
subsequent liver test results and resolution of biochemical abnormalities. Laboratory results 
meeting any one of the above criteria, along w ith a copy of baseline laboratory results, must 
be sent to the the sponsor within 24 hours of becoming aware of the results. Wherever 
possible, the investigator should a rrange for the subject to return to  the clinical site as soon as 
possible (within 24 hours of notice of abnormal results) for repeat assessment of laboratory 
results to confirm that the subject meets the trial discontinuation criteria as well as to obtain detailed history and to perform a physical ex amination. Subjects should be followed with 
frequent (every 24 to 48 hours) repeat clini cal laboratory assessment and any other 
appropriate assessm ents until all abnor malities normalize (in the inve stigator’s opinion) or 
return to the baseline state. The subject will be discontinued from the study and returned to 
the study site for repeat and follow-up assessm ents. These follow-up steps are outlined in 
more detail in a separate  procedures document. 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 41 of 72 
  
 In addition, the severity of  all instances of DILI are to be a ssessed according to the International 
DILI Expert Working Group’s severity index15 (Appendix D). This severity assessment will 
occur in addition to the AE reporting procedures  detailed in 4.7.3.1.2 (Adverse  Event Reporting).  
4.7.3.3 Vital Sign Measurements Vital signs (blood pressure, hear t rate, respiratory rate, and oral body te mperature) will be 
measured using an automated device at the time points presented in the Schedule of Events ( and B). Vital signs may be repeated  at investigator discretion. 
4.7.3.4 Safety 12-lead Electrocardiograms 
12-lead ECGs will be obtained with the subjects in the supine position before recording. ECGs 
will be overread by a physician. If an abnormality is observed, the subject will be instructed to 
follow up with his or her personal physician. 
4.7.3.5 Physical Examinations 
A complete physical examination will be performed  at the time points presented in the Schedule 
of Events (Appendix A and B). 
The complete physical examinati on will include, but not be limited to, assessments of the head, 
eyes, ears, nose, throat, skin, thyroid, nervous sy stem, respiratory system, cardiovascular system, 
abdomen (liver and spleen), ly mph nodes, and extremities. Hei ght, weight (without shoes and 
wearing the lightest possible cl othing), and calculation of body ma ss index will be performed at 
Screening and check-out. 
If a clinically significant abnormality is observe d upon physical examination, the subject will be 
instructed to follow up with his or her personal physician. 
4.7.4 Demographics and Medical History 
Demographic data (date of birth, gender, race, and ethnicity) will be collected at Screening. 
Each subject will provide a complete medical history at Screening that will be reviewed at 
check-in. Specific information relating to any prior or existing medical conditions/surgical 
procedures will be recorded in the subject’s eCRF. 
4.8 Study Treatments 
4.8.1 Dose Selection and Rational  
Cannabidiol (Epidiolex) oral solution will be obt ained for 190 participants (150 in Part 1 and 40 
in Part 2) to receive cannabidiol twice daily as per the Schedule of Ev ents. All dosing will be 
oral. Anticipated dosing is 5 mg/kg/day administe red in divided doses twice daily (i.e. 2.5 mg/kg 
twice daily). Oral placebo solution (matching characteristics of cannabidiol solution) will be obtained for 50 participants in Part 1 to receive placebo twice daily as per the schedule of events. 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 42 of 72 
  
 Cannabidiol’s label indicates a maximum dosag e of 20 mg/kg/day, therefore the proposed study 
dose of 5 mg/kg/day is lower than the maximum therapeutic dose noted in the label. Data from a recent meta-analysis marked 400 mg/day as an upper limit of what can be considered low dose CBD and attainable using ove r the counter CBD products.
16 In this study, total daily dosing will 
be in line with this threshold (200 mg twice daily for an 80 kg person). The anticipated DDI 
substrate drugs are oral morphine and oral citalopram. Of the participants in Part 2, 20 will receive morphine and 20 will receive citalopram as per the schedule of events.  
4.8.2 Treatments Administered and Schedule Study drugs for both parts will be administered by a clinical research nurse on the study clinic 
floor during check-ins and in-house stays. The pha rmacist or investigator  will be available if 
needed during study drug administration. Oral st udy drugs (Part 2) will be administered with 
240 mL of room -temperature water. During study  days not on site, subj ects will be required to 
take the study drugs twice daily at home. A memb er of the study team will follow up daily with 
each subject to ensure compliance with dosing schedule. Because levels of CBD may be affected by food, subjects will be instructed to take CBD c onsistently with regards to meals. Subjects will 
be instructed to take CBD af ter eating breakfast and dinner during at-home days. During in-
house stays, CBD will be given a pproximately 30 minutes after the start of breakfast and dinner. 
A fasting period of 4 hours will be required before all time points when clinical laboratory samples will be obtained. In add ition, for Part 1, a fasting period of 8 hours will be required prior 
to lipid profile sampling on check-out Days 1 and 29. 
For Part 1 and Part 2, each instance of prima ry study drug administration will consist of an 
identical volume of prepared study drug oral so lution. Placebo solution will be used to match 
treatments when needed. A study drug diary, design ed by the clinical site and approved by the 
local IRB, will be given to each subject to m onitor study drug tolerance and patient outcomes. 
4.8.2.1 Method of Assigning Subjec ts to Treatment Sequence 
4.8.2.1.1 Randomization Process 
The project biostatistician will create the specifications that will be used to generate the 
randomization schedule. The specifications will be based on the protocol requirements and appropriate statistical progra mming with consideration for st udy design, number of treatments, 
number of subjects planned for enro llment, stratificati on, and blocking. 
Based on these specifications, the project biostatistician (or designee) will generate a dummy 
randomization schedule. The sche dule is generated in R.  
The project biostatistician (or designee) dist ributes the ‘dummy’ randomization schedule to 
specified personnel and pharmacy for review. Any change (e.g., change in block size, change in 
stratification levels) that requires an update to the specifications will reset this process. Minor changes (e.g., display formatting) will not require a change to the specifications. 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 43 of 72 
  
 After the approval of the ‘dummy’ randomizati on schedule, the project biostatistician (or 
designee) transfers the program used to gene rate the ‘dummy’ schedule to the randomization 
biostatistician (unblinded), who is an independent party and will not be participating in any programming or statistical decisi ons for the study before breaking the blind. No transfer is 
necessary if the unblinded randomization bi ostatistician also created the ‘dummy’ 
randomization. 
The randomization biostatistician is  responsible for generating the final randomization schedule. 
The output is sent only to designated unblinded recipients, who will maintain a secured digital and printed copy for their use. 
Archival of the programs and output is accomplished by the creation of an encrypted, password-
protected ZIP file containing the program and output file(s). The ZIP file is copied to a secure 
storage drive on the sponsor’s site. 
Randomization will occur after informed consent is obtained in Part 1, either after completion of 
check-in procedures on Day -1 or just before  dosing on Day 1. Approxima tely 200 healthy male 
and female subjects are planned for enrollment  in Part 1 (150 subject receiving CBD and 50 
receiving placebo). 
All randomization information will be secured and housed in a lo cked storage area, accessible 
only by the randomization personnel and the assi gned pharmacist and his or her verifier. 
4.8.2.1.2 Identity of Study Drugs 
Cannabidiol (Epidiolex) is indi cated for the treatment of se izures associated with Lennox-
Gastaut syndrome, Dravet syndrome, or tuber ous sclerosis complex. It is extracted from 
Cannabis sativa L. plants. Cannabidi ol (Epidiolex) is a clear, colo rless to yellow liquid available 
in 100 mg/mL oral solution. The compound cannabidi ol is a white to pale yellow crystalline 
solid, insoluble in water but soluble in organic solvents. Cannabidiol has a molecular weight of 
314.46, and molecular formula is C21H30O2.2 
Citalopram (Celexa) is a selective serotonin reupt ake inhibitor (SSRI) indicated for treatment of 
major depressive disorder. Cital opram hydrobromide occurs as a fine, white to off-white powder, 
and sparingly soluble in water a nd ethanol. Citalopram (Celexa) is  orally administrated tablet 
available as 10 mg, 20 mg, and 40 mg stre ngth tablets contain 12.49 mg, 24.98 mg, and 49.96 
mg of citalopram hydrobromide, respectively. C italopram has a molecu lar weight of 405.35, and 
molecular formula is C20H22BrFN2O.11 
Morphine sulfate tablet is an opioid agonist i ndicated for the management of moderate-severe 
acute and chronic pain. It is available in 15 mg and 30 mg for oral administration. Morphine 
sulfate USP is a white to off-white crystalline powde r or a fine white to light yellow powder, it is 
soluble in water and slightly soluble in alcohol but is practically insoluble in chloroform or ether. 
Morphine sulfate has a molecular wei ght of 668.80, and molecular formula is 
C34H40N2O10S.12 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 44 of 72 
  
 Placebo solution will be supplie d by the clinical site.  
4.8.3 Management of Clinical Supplies 
4.8.3.1 Study Drug Pack aging and Storage 
The active study drugs will be obtained from commer cial sources. Storage instructions for the 
active study drugs are as follows: 
x Cannabidiol solution should be stored at 20° to 25°C (68° to 77°F) with excursions 
permitted from 15° to 30°C (59° to 86°F). Do not refrigerate or freeze. Use within 12 weeks of first opening the bottle, then discard any remainder.
2 
x Citalopram tablets should be st ored at 25°C (77°F) with excursions permitted from 15° to 
30°C (59° to 86°F).11 
x Morphine tablets should be stored at 20° to 25°C (68° to 77°F) and protected from 
moisture.12 
Placebo solution will be supplied by the clinical  site and stored per USP requirements. 
4.8.3.2 Study Drug Accountability 
Good clinical documentation practices will be empl oyed to record the receipt, storage conditions, 
accountability, and use or return of the study drug . The study drug will be stored in a secure 
location with access to the study personnel who wi ll be managing the storage, dispensing, and 
accountability of the study drug. 
Upon completion or termination of the study, fi nal accountability review by the study monitor, 
and written authorization from the sponsor, all unused and/or par tially used study drug should be 
returned or destroyed at the study clinic. It is th e investigator’s responsibility to ensure that the 
sponsor has provided written aut horization for study drug disposal , the disposal process follows 
the study clinic’s standard opera ting procedures, and a ppropriate records of the disposal are 
documented and maintained. No unused study drug may be disposed until fully accounted for by 
the study monitor (or designee). Documentation of unused study drug should include subject 
number, medication identity (medication #, peri od #), date, and quantity  of study drug used. 
4.8.4 Blinding 
Part 1 of the study will be double-blind, a nd the blind will be maintained through a 
randomization schedule held by the dispensing pha rmacist. The pharmacist  (and designated staff 
member responsible for confirma tion of study drug dose) will be unblinded to subject treatment 
assignment; however, the pharmacist will not pe rform any study procedures other than study 
drug preparation and dispensing.  
 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 45 of 72 
  
 Additional details regard ing blinding can be found in the Sp aulding Blinding SOP which will be 
followed to ensure the blind is maintained throughout the study. 
4.8.4.1 Breaking the Blind The study drug blind will not be broken by the in vestigator or designee unless information 
concerning the study drug is necessary for the me dical treatment of the subject. For unblinding a 
subject, the randomization information for unblinding can be obtained by contacting the 
dispensing pharmacist. The sponsor or medical m onitor must be notified immediately if the study 
drug blind is broken. The date, time, and reason that the blind was broken will be recorded in the source documents. If the blind is broken by the i nvestigator or designee, the study drug must be 
stopped immediately, and the subject must be w ithdrawn from the study. Data or specimens 
already collected from subjects who discontinue prematurely and for whom the blind is broken 
will be made available for analysis if needed.
 
4.8.5 Treatment Compliance 
For in-house visits, all doses of the study drug w ill be administered in th e study clinic either 
under direct observation of or ad ministered by clinic pe rsonnel and recorded in the eCRF. If a 
subject vomits after dosing, the event will be documen ted as an AE. For outpatient days, subjects 
will be contacted daily by clinical site staff regarding dosing and reminded to consistently take the study drug approximately 30 minut es after the start of breakfas t and dinner. For out-patient 
visits or second check-in days, an inventory of study drug consumed and study drug remaining 
will be completed. 
4.8.6 Prior and Concomitant Medications Subjects are prohibited from using any prescrip tion or nonprescription drugs (including aspirin 
or NSAIDs and excluding  contraceptives) within 14 days or 5 half-lives (whichever is longer), 
or complementary and alternativ e medicines within 28 days before the first dose of study drug. 
This includes prescription or nonprescription opht halmic drugs. Note the only drugs permitted 
are contraceptives. Subjects will be asked if they have used any of medication and their responses will be recorded on the eCRF. 
Subjects are also prohibited fro m currently participating in another clinical study of an 
investigational drug and ma y not have been treated with any investigational dr ug within 30 days 
or 5 half-lives (whichever is longer) of the compound. 
Subjects must be instructed not to take a ny medications, including over-the-counter products, 
without first consulting with the investig ator. During the study, low dose acetaminophen or 
ibuprofen may be allowed with inves tigator's approval for minor symptoms. 
4.8.7 Subject Restrictions 
Subjects are not allowed to us e nicotine containing products (e .g., cigarettes, cigars, chewing 
tobacco, snuff, electronic cigarettes) within 6 weeks before Screening. In addition, subjects are 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 46 of 72 
  
 not allowed to ingest alcohol, xa nthine containing products (e.g., te a, coffee, chocolate, cola), 
caffeine, kava melatonin, St Johns Wart, grapefru it, or grapefruit juice within 24 h of check-in of 
all study periods. Subject must refrain from inge sting alcohol, xanthine containing products (e.g., 
tea, coffee, chocolate, cola), caffeine, kava melatonin, St Johns  Wart, grapefruit, or grapefruit 
juice throughout the entire study. S ubjects are not allowed to use aspirin or NSAIDs within 
14 days before the first dose of study drug. Subjects  will be asked if they have used any of these 
substances and their responses will be recorded on the eCRF. 
Subjects must be able to tolerate a cont rolled, quiet study conduct environment, including 
avoidance of music, television, movies, games, and activities that may cause excitement, emotional tension, or arousal during prespecified times throughout the duration of the study. 
Subjects must be willing to comply with study rules; attempting to void at specified times; 
remaining quiet, awake, undistr acted, motionless, and supine  during specified times; and 
avoiding vigorous exercise as directed  throughout the duration of the study. 
A fasting period of at least 4 hours will be required before all time points when clinical 
laboratory samples will be obtained. In Part 1, all subjects will fast overnight for a minimum of 8 
hours (no food or fluid except water) before blood collection for lipid testing on check-out days 1 
and 29. Standardized meals will be served at consistent times relative to dosing for in-house 
days, and no food or fluids will be  served containing caffeine. Ou tside of mealtimes, the subjects 
will only be allowed to intake water, which will be available ad libitum. Due to current precautions being taken for COVID-19, the fo llowing restrictions will be in place: 
x Subjects should be encouraged to wear masks ex cept when in a private room without anyone 
else present or for a limited time for a study procedure (e.g., study drug administration or 
eating) when instructed by staff.  
x Subjects must practice social distancing, which will include  having a maximum of 2 subjects 
per room for overnight stays and access to common areas will be per clinical research site standards. While subjects are in house, meals will be served per clinical research site 
standards. Subjects will spend most of their time in their rooms except for specified times for walking in the halls (with masks recommended). 
x Subjects must practice regular ha ndwashing with soap and water, scrubbing hands for at least 
20 seconds or with approved hand sa nitizer as supplied by study staff.  
Designated isolation rooms will be set up to segregate any participant(s) that develop any 
symptoms of concern while housed in the unit and COVID-19 testing will be done when deemed 
necessary by the Investigator. If new informa tion becomes available, there could be other 
precautions that lead to additional restrictions  that will be documented in the COVID-19 Risk 
Management Plan and/or the study specific COVID-19 Procedure Plan. 
4.9 Statistical Methods 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 47 of 72 
  
 4.9.1 Sample Size 
A total of 240 healthy subjects are planned for en rollment and approximately  190 of these will be 
administered CBD. The primary endpoint is the pe rcentage of CBD admin istered participants 
with an ALT (based on consensus criteria*) or AST liver enzyme elevation greater than three 
times the ULN.  Assuming the true event rate is 6%, the study has 95% probability of observing 
5 or more events with ALT or AST liver enzyme elevation greater than three times the ULN. Assuming the true observed drug-induced liver in jury event rate is 2%, the study has a 93% 
percent probability of observing 1 or more event. 
In Part 1, change from baseline comparisons will be performed for various  endocrine laboratory 
measures (e.g., total testosterone , inhibin B, TSH, total T3, and free T4). Sample size for the 
study is not powered for any of these compar isons nor are any adjustments planned for 
multiplicity.  
In Part 2, comparisons will be performed on ch anges in exposure for two different substrate 
drugs following administration with CBD. Assu ming no more than 20% discontinuations per 
arm, 30% intra-subject variability, and a two-side d test at the 0.05 significance level, the sample 
size would have 90% power to detect a 30% diff erence in exposure when the substrate drugs are 
co-administered with CBD.  
4.9.2 Analysis Populations 
Part 1 
The liver safety analysis population will include all subjects who receive at least 1 dose of any of 
the study drugs and have liver lab data (ALT and AST) for the tr eatment period collected before 
dosing and at 1 or more time points after dosi ng. The liver safety analysis population will be 
used for all liver safety analyses. 
The laboratory analysis population will include  subjects that have laboratory/proteomics 
measures (e.g., free and total test osterone, inhibin B, TSH, to tal T3, free T4, lipid panel, 
proteomics) from pre-dose on Day 1 and check-out on Day 29 (time-matched to Day 1). The laboratory population will be used for all analyses involving change from baseline in 
laboratory/proteomics measures.  
The safety population will include all subjects who receive at least 1 dose of the study drug. 
Part 2 
The PK population will include all subjects who receive the study drug and have at least 1 
estimable PK parameter after dosing with the substrate drug alone and with the substrate drug in combination with CBD.  
The safety population will include all subjects w ho receive at least 1 dose of the study drug. 
4.9.3 General Statistical Considerations 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 48 of 72 
  
 All data will be presented in data listings. Data from subjects excluded from an analysis 
population will be presented in th e data listings, but not included in the calculation of summary 
statistics. Demographic and baseline characteristics will be summarized overall and by treatment for all subjects. 
4.9.4 Subject Disposition The number of subjects who enroll in the study and the number and percentage of subjects who 
complete each assessment will be presented. Th e frequency and percenta ge of subjects who 
withdraw or discontinue from the study and the re ason for withdrawal or discontinuation will be 
summarized. 
4.9.5 Demographics and Ba seline Characteristics 
Descriptive statistics will be used to summarize demographic and baseline subject 
characteristics. For continuous variables, the mean, median, standard deviation (SD), minimum, 
and maximum values will be reported. For categorical (nominal) variables, the number and percentage of subjects (or observations) will be reported. 
4.9.6 Primary and Secondary Analyses Part 1  
The primary endpoint is the percentage of subject s with an ALT (based on consensus criteria) or 
AST liver enzyme elevation greater than thr ee times the upper limit of normal (ULN). Results 
will be reported as percen tage with a 95% confidence interval .  The secondary liver endpoint is 
the percentage of participants meeting withdrawal criteria for potential drug-induced liver injury. Analysis and reporting will be perform ed similar to the primary endpoint. 
Secondary endpoints involving labor atory measures will include the changes from baseline in 
serum total testosterone  and inhibin B in males after CBD administration compared to placebo. 
Change from baseline in thyroid stimulating hormone, total T3, and free T4 in both males and females after CBD administration compared to placebo will also be assessed. These analyses will use a mixed-effect analysis approach. The model will include treatment as fixed effects and subject as a random effect. Testing will be two-sided, and a significant increase will be 
concluded if the two-sided 95% CI  excludes 0. In addition, the percen tage of subjects with either 
abnormal total testos terone (males only) or abnormal la boratory tests will also be reported. 
Results will be presented as point estimates with associated 95% CI. 
Part 2 
The primary analysis for Part 2 will be a comp arison of the area under the plasma concentration-
time curve (AUC) and C max of citalopram or morphine when administered alone versus when co-
administered with CBD (for morphine, this will in clude after co-administration with CBD for 1-
day and 7-days). The PK parameters (AUC and C max) will be analyzed using noncompartmental 
methods based on actual sampling times. Using li near mixed-effects modeling, comparisons of 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 49 of 72 
  
 log-transformed PK parameters will be performed. Treatment will be a fixed effect. Subject will 
be included as a random effect on the intercept.  Treatment differences on the log-scale will be 
estimated for the PK parameters. Geometric mean ratio and 90% CI will be obtained by exponentiation of the treatment effect and 90% CI based on the log-transformed scale.  
For the secondary PK endpoints, AUC and C
max for morphine metabolites (alone and when co-
administered with CBD) will be an alyzed using the same approach as the primary PK endpoints. 
4.9.6.1 Additional Analyses 
Part 1 
Assessment of liver-related adverse events will be performed consistent with FDA’s Guidance 
for Industry on Drug-Induced Liver Injury: Premar keting Clinical Evaluation. This will include 
but is not limited to the following categorical and visual summaries: 
x 3x-, 5x-, 10x-, and 20x ULN elevations of AST, ALT, and either ALT or AST. 
x Any elevations of bilirubin; elevated TBL to >2x ULN. 
x Any elevations of ALP >1.5xULN. 
x Elevation of ALT or AST (>3x ULN) accompanied by elevated bilirubin (>1.5x ULN, 
>2x ULN). 
x Elevation of ALT or AST in temporal a ssociation with nausea, vomiting, anorexia, 
abdominal pain, or fatigue. 
Portions of collected blood samples from this  study will be used for evaluating laboratory 
measures and differentially expr essed plasma proteins. Additiona l details regarding the methods 
for the exploratory analyses will be described in a separate protocol. Steady state CBD and metabolite drug concentrations will be summarized by visit using descriptive statistics. 
Part 2 
Additional exploratory PK parameters for citalopram, morphine, CBD, and metabolites, such as 
time of maximum concen tration, half-life, apparent clea rance, and apparent volume of 
distribution will be analyzed using noncompartme ntal methods based on actual sampling times. 
All parameters will be calculated using statistical software. Mean and individual concentration time profiles will be presented in graphs. 
4.9.10 Safety Analyses 
 4.9.10.1 Adverse Events All AEs will be coded using the latest version of the Medical Dictionary for Regulatory 
Activities. The incidence of TEAEs, organized by system organ class and frequency, will be 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 50 of 72 
  
 summarized by seriousness, severit y, relationship to trea tment, and by treatment at onset of the 
TEAE. A detailed listing of serious AEs and TEAEs leading to withdrawal will also be provided. 
 4.9.10.2 Clinical Laboratory Tests Clinical laboratory results will be reviewed by the investigator or designee together with data in 
the eCRF. Any values outside the reference range will be evaluated for clinical significance. If a value is determined to be clinically significant, the subject will be instructed to follow up with his or her personal physician. Th e investigator or designee may repeat the clinical laboratory 
tests if deemed appropriate. The investigator w ill maintain a copy of th e laboratory accreditation 
and the reference ranges for the laboratory used. 
Clinical laboratory results (hematology, serum chemistry, and urinalys is) will be summarized 
using descriptive statistics ( number of subjects, mean, SD, minimum, median, and maximum). 
Clinical laboratory results will be  classified as normal or abnormal, according to the reference 
ranges of the individual parameter. The number and percentage of s ubjects with abnormal 
laboratory results will be provided. No statistical testing will be performed on clinical laboratory data. 
 4.9.10.3 Vital Sign Measurements Vital sign measurements and changes from baseline will be summarized using descriptive 
statistics (number of subjects,  mean, SD, minimum, median, a nd maximum) by treatment and 
time points as specified in Section 4.7.3.3. 
  4.9.10.4 Safety 12-lead Electrocardiograms  
12-lead ECGs will be obtained with the subjects in the supine position for a minimum of 10 
minutes before recording. ECGs  will be overread by a physician or  other trained clinical team 
staff. If an abnormality is observed, the subject will be instructed to follow up with his or her 
personal physician. 
 4.9.10.5 Physical Examinations  Physical examination findings will be presen ted in a data listing, and abnormal physical 
examination findings will be recorded as AEs.
 
 4.9.10.6 Other Safety Data 
All concomitant medication usage and medications that changed in daily dose, frequency, or 
both since the subject provided informed consent will be summarized for each subject.  
4.9.11 Interim Analyses 
No interim analyses are planned.  
4.9.12 Missing Data 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 51 of 72 
  
 Missing data will not be imputed. Data that are excluded from the descriptive or inferential 
analyses will be included in the subject data listings. This will include data from subjects not in the particular analysis populati on, measurements from unscheduled visits, or extra measurements 
that may arise from 2 or more analyses of the biofluid sample at the same time point. Details on the handling of missing data will be further descri bed in the Statistical Analysis Plan (SAP). 
4.10 Data Quality Assurance 
Completed eCRFs are required for each subject randomly assigned to trea tment. Electronic data 
entry will be accomplished through the ClinSpark® remote electronic data capture system, which 
allows for on-site data entry and data management. This system provides immediate, direct data transfer to the database, as well as immediate detection of discrepancies, enabling site coordinators to resolve and mana ge discrepancies in a timely ma nner. Each person involved with 
the study will have an individua l identification code  and password that allows for record 
traceability. Thus, the system, and subsequently any investigative reviews, can identify coordinators, investigators, and individuals who have ente red or modified records. 
 Furthermore, the investigator retains full respons ibility for the accuracy and authenticity of all 
data entered into the electronic data capture sy stem. The completed dataset and their associated 
files are the sole property of the sponsor and shoul d not be made available in any form to third 
parties, except for appropriate governmental h ealth or regulatory aut horities, without written 
permission of the sponsor. 
4.11 Data Sharing 
De-identified subject-leve l data may be released to other researchers (including through a data 
warehouse or as a part of a publication) to en able secondary researc h. Additional secondary 
research may also be performed by the sponsor. 
5. ETHICAL CONSIDERATIONS 
5.1 Ethical Conduct of the Study 
This study will be performed in accordance w ith the recommendations guiding physicians in 
biomedical research involvi ng human subjects adopted by the 18th World Medical Association 
General Assembly, Helsinki, Finl and, 1964 and later revisions, as well as United States Title 45 
Code of Federal Regulations (CFR) Part 46 GC P, and International Council for Harmonisation 
(ICH) guidelines describing technical requirements for registration of pharmaceuticals for human use. 
5.2 Institutional Review Board (IRB) 
The FDA Project Lead or investigator will provide the designated IRB with all required documents, including the study protocol and in formed consent form. The study will not be 
initiated until appropriate IRB approval is obtained from the designated IRB. The investigator 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 52 of 72 
  
 will provide the FDA Project Lead with copies of the approval documents for the protocol, 
informed consent form, and all recruiting materials. The designated IRB will also receive copies of any original or amended information sheets or  pamphlets given to the study subject in support 
of the informed consent process and any adver tisements or other recruitment material. Such 
materials will not be employed in the study before approval by the designated IRB. 
 Subjects will be informed that they have the right to contact the IRB or Office for Human Research Protections if they have  any questions, concerns, complain ts, or believe they have been 
harmed by the participation in this research study as a result of investigator negligence. Subjects 
will be given the address a nd phone number of the IRB. 
6. ADMINISTRATIVE PROCEDURES 
6.1 Responsibilities of the Investigator  
The following administrative items are meant to guide the investigator in the conduct of the 
study but may be subject to change based on industry and government standard operating 
procedures, working practice documents, or guideli nes. Changes may be re ported to the IRB but 
will not result in protocol amendments. 
6.1.1 Form FDA 1572 The investigator will complete and sign the Form FDA 1572. 
6.1.2 Adherence to Protocol  
The investigator agrees to conduct the study as ou tlined in this protocol in accordance with the 
ICH E6(R2) and all applicable  guidelines and regulations. 
6.1.3 Reporting Requirements  By participating in this study, th e investigator agrees to submit reports of SAEs according to the 
timeline and method outlined in the protocol. In addition, the investigator agrees to submit 
reports to the IRB as appropriate. The investigator  also agrees to provide the sponsor with an 
adequate report shortly after completion of the investigator’s participation in the study. 
6.1.4 Source Documentation 
By participating in this study, the investigator agrees to maintain adequate case histories for the 
subjects treated as part of the research under this  protocol. The investigat or agrees to maintain 
accurate eCRFs and source documentation as part of the case histories. 
6.1.5 Retention of Records  
The investigator agrees to keep the records stipul ated in this protocol and those documents that 
include (but are not limited to) the study-sp ecific documents, identification log of all 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 53 of 72 
  
 participating subjects, medical re cords, source worksheets, all orig inal signed and dated informed 
consent forms, subject authoriza tion forms regarding the use of personal health information (if 
separate from the informed consent form), copi es of all eCRFs, query  responses, and detailed 
records of drug disposition, to enable evaluati ons or audits from regulatory authorities, the 
sponsor, or its designees. 
Furthermore, ICH 4.9.5 requires the investigator to retain essential doc uments specified in 
Section 8 of ICH E6(R2) until at least 2 years af ter the last approval of a marketing application 
for a specified drug indication being investigated or, if an application is not approved, until at least 2 years after the investigation is discontinued and regulatory authorities are notified. In addition, ICH 4.9.5 states that the study records should be retained until an amount of time 
specified by applicable regulatory requirements or for a time specified in the clinical study site 
agreement between the investigator and sponsor. 
Refer to the clinical study site agreement for th e sponsor’s requirements on record retention. The 
investigator should contact and receive written approval from the sponsor before disposing of 
any such documents. 
6.1.6 Financial Disclosure and Obligations 
The investigator is required to provide financial disclosure info rmation to allow the sponsor to 
submit the complete and accurate  certification or disclosure  statements required under 
45 CFR 46. In addition, the investigator must provi de to the sponsor a commitment to update this 
information promptly if any rele vant changes occur during the cour se of the investigation and for 
1 year after the completion of the study. 
Neither the sponsor nor the study c linic is financially responsible for further testing or treatment 
of any medical condition that may be de tected during the screening process. 
6.2 Confidentiality and Disclosure of Data 
All subjects will sign a HIPAA compliant authorization form containing the mandated core 
elements and requirements before participation in this clinical  study. The sponsor and designees 
affirm and uphold the principle of  the subject’s right to protec tion against invasion of privacy. 
Throughout this study, a subject’s source data will only be linked to the s ponsor’s electronic data 
capture system database or documentation via a unique identification number. As permitted by all applicable laws and regulations, limited subject attributes such as gender, age or date of birth, and subject initials may be used to verify the subject and accuracy of the subject’s unique identification number. 
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the 
sponsor requires that the investig ator allow review of the subj ect’s original medical records 
(source data or documents) by the study monitor,  representatives from any regulatory authority 
(e.g., FDA), the sponsor’s designated auditors, an d the appropriate IRB. These medical records 
will include, but will not be limited to, clinical laboratory test result reports, ECG reports, 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 54 of 72 
  
 admission and discharge summaries for hospita l admissions occurring during a subject’s study 
participation, and autops y reports. Access to a subject’s orig inal medical records requires the 
specific authorization of the subject as part of the informed consent process. 
Copies of any subject source doc uments that are provided to th e sponsor must have personally 
identifiable information removed (i.e., subject na me, address, and other identifier fields not 
collected in the subject’s eCRF). 
Data will be maintained and backed up in the electronic data capture system. All access to the 
data is protected by username and password, and each staff memb er and all sponsor staff will 
have separate access that requires  a separate username and password.  Access is only given to site 
staff and requested sponsor staff who ha ve completed the appropriate training. 
6.3 Subject Consent 
Written informed consent in compliance with 45 CFR 46 will be obtained from each subject 
before entering the study or perfo rming any unusual or nonroutine proc edure that involves risk to 
the subject. An informed consent template may be provided by the sponsor to the study clinic. If 
any institution-specific modifications to study rela ted procedures are proposed or made by the 
study clinic, the consent should be reviewed by th e sponsor or its designee or both before IRB 
submission. Once reviewed, the consent will be submitted by the investigator to the IRB for 
review and approval before the start of the study. If the informed consent form is revised during 
the course of the study, all active participating subjects must sign the revised form. 
Before enrollment, each prospective subject will be  given a full explanation of the study and be 
allowed to read the approved informed consent form. The informed consent process will be performed by a clinical research nurse in a private room. The subject will be given unlimited time to ask questions regarding st udy participation, and each subject  will be questioned to ensure 
their understanding. Once the investigator is assu red that the subject understands the implications 
of participating in the study, the subject will be asked to give c onsent to participate in the study 
by signing the informed consent form. 
The investigator will provide a copy of the signed  informed consent form to the subject. The 
original form will be maintained in the subject’s medical records at the site. 
6.4 Data Collection 
Full details of procedures for data collection and handling will be documented in the data management plan, which is initiated with the final protocol receipt. The data management plan is a changing document that evolves over the course of the study and is finalized by database lock. 
6.5 Publications 
No information related to or generated by this study will be re leased to the public until it has 
been reviewed by the sponsor. The sponsor shall own intellectual rights for the data and analysis 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 55 of 72 
  
 resulting from this study. Authorship on publications  will be determined by standard journal 
requirements. 
7. STUDY MANAGEMENT 
7.1 Monitoring 
The sponsor or its designee will monitor the study to ensure that it is being conducted according 
to the protocol, GCP standards, and applicable region-specific requi rements, and to ensure that 
study initiation, conduct, and closur e are adequate. The investigat ors and the study clinic staff 
will be expected to cooperate fully with the study monitors and personnel or agents of the 
sponsor and be available during monitoring visits to answer questions sufficiently and to provide 
any missing information. The investigators and th eir institutions will permit direct access to 
source data/documents for study related monito ring activities, audits, IRB reviews, and 
regulatory inspections. 
During any on-site visits, the study monitor will:  
x Check and assess the progress of the study 
x Review all informed consent forms 
x Review study data collected 
x Conduct source document verification 
x Identify any issues and address their resolution 
x Verify that the facility remains acceptable 
x Conduct study drug accountability 
These monitoring activities will be done in order to verify that the:  
x Data are authentic, accurate, and complete. 
x The safety and rights of the subjects are being protected. 
x The study is being conducted in accordance with  the currently approved protocol (including 
any amendments), GCP, and all a pplicable regulatory requirements. 
In addition, the sponsor, designate d auditors, and government inspect ors must be allowed access 
to eCRFs, source documents, and other study file s that may be required to evaluate the conduct 
of the study. 
7.2 Management of Protocol Amendments and Deviations 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 56 of 72 
  
 7.2.1 Modification of  the Protocol 
Any changes in this research activity, except those necessary to remove an apparent immediate 
hazard to the subject, must be submitted to the sponsor or designee and reviewed and approved 
by the local IRB before implementation. Amendmen ts to the protocol must be submitted in 
writing to the investigator’s IRB for approval before subjects are enrolled into an amended 
protocol. 
7.2.2 Protocol Violatio ns and Deviations 
Any significant protocol deviations that the investigator or study c linic staff believes are of major 
importance (e.g., incorrect randomizations, subject enrolled but not eligible) should be reported 
to the sponsor and the investigator’s IRB as s oon as possible. Significan t protocol deviations 
may include the following: 
x Deviations from the inclusion/exclusion criteria that may affect subject safety 
x Deviations (omission or delay) of  safety monitoring procedures 
x Deviations in the administration of the study drug 
x Deviations in obtaining informed consent 
All subjects who are enrolled and receive the st udy drug, regardless of whether they have a 
major protocol violation, must c ontinue to be followed for safe ty for all follow-up study visits. 
 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 57 of 72 
  
 Reference list 
1. U.S. Food and Drug Administration (FDA) Science Board. (2022, June 3). Background 
materials for the June 14, 2022 meeting of th e Science Board to the FDA. Retrieved from 
https://www.fda.gov/advisory-committees/advi sory-committee-roster/science-board-
fda/2022-meetings#event-materials . 
2. Cannabidiol (Epidiolex ®) or al solution label obtained from 
https://www.accessdata.fda.gov/drugs atfda_docs/label/2018/210365lbl.pdf 
3. Lo, LA, Christiansen, A, Eadie, L, Stri ckland, JC, Kim, DD, Boivin, M, et al. 
Cannabidiol-associated hepatot oxicity: A systematic review and meta-analysis. J Intern 
Med. 2023; 293: 724–752. 
4. Crippa JAS, Zuardi AW, Guimarães FS, et al. Efficacy and Safety of Cannabidiol Plus 
Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and 
Burnout Among Frontline Health Care Wo rkers During the COVID-19 Pandemic: A 
Randomized Clinical Trial. JA MA Netw Open. 2021;4(8):e2120603. 
doi:10.1001/jamanetworkopen.2021.20603 
5. U.S. Food and Drug Administration (FDA). Clinical Pharmacology and 
Biopharmaceutics Review . Retrieved from 
https://www.accessdata.fda.gov/drugsatfd a_docs/nda/2018/210365Orig1s000ClinPharm
R.pdf  
6. EFSA NDA Panel (EFSA Panel on Nutrition, N ovel Foods and Food Allergens), Turck, 
D, Bohn, T, Castenmiller, J, De Henauw, S, Hirsch-Ernst, KI, Maciuk, A, Mangelsdorf, I, 
McArdle, HJ, Naska, A, Pelaez, C, Pentieva, K, Siani, A, Thies, F, Tsabouri, S, Vinceti, M, Cubadda, F, Frenzel, T, Heinonen, M, Marc helli, R, Neuhäuser-Berthold, M, Poulsen, 
M, Prieto Maradona, M, Schlatter, JR, Trezza, V, van L overen, H, Albert, O, Dumas, C, 
Germini, A, Gelbmann, W, Kass, G, Kouloura,  E, Noriega Fernandez, E, Rossi, A and 
Knutsen, HK, 2022. Statement on safety of canna bidiol as a novel food: data gaps and 
uncertainties. EFSA J ournal 2022; 20(6):7322, 25 pp. 
https://doi.org/10.2903/j.efsa.2022.7322  
7. Carvalho, RK, Andersen, ML, Mazaro-Costa, R. The effects of cannabidiol on male 
reproductive system: A lite rature review. J Appl Toxicol. 2020; 40: 132–150. 
https://doi.org/10.1002/jat.3831  
8. Tallon, MJ, Child, R. Subchronic oral toxi city assessment of a cannabis extract. 
Regulatory Toxicology and Pharmacology. 2023; 144. https://doi.org/10.1016/j.yrtph.2023.105496 . 
9. Anderson, LL, Doohan, PT, Oldfield, L, Ke vin, RC, Arnold, JC, Berger, M, Amminger, 
PG, McGregor, IS. Citalopram  and Cannabidiol: In Vitro and In Vivo Evidence of 
Pharmacokinetic Interactions Relevant to the Treatment of  Anxiety Disorders in Young 
U.S. FOOD AND DRUG ADMINISTRATION  
 Protocol Number: SCR-016 
(Version 3.0) 
 
CONFIDENTIAL Page 58 of 72 
  
 People. Journal of Clinical Ps ychopharmacology. 41(5):p 525-533, DOI: 
10.1097/JCP.0000000000001427 
10. Armstrong, SC, Cozza, KL. Pharmacokinetic Dr ug Interactions of Morphine, Codeine, 
and Their Derivatives: Theory and Clini cal Reality, Part I. Psychosomatics. 2003, 
44:2:167-171. https://doi.org/10.1176/appi.psy.44.2.167. 
11. Citalopram (Celexa ®) ta blet label obtained from 
https://www.accessdata.fda.gov/drugs atfda_docs/label/2022/020822s041lbl.pdf 
12. Morphine Sulfate tablet label obtained from 
https://www.accessdata.fda.gov/drugs atfda_docs/label/2021/022207s010lbl.pdf 
13. Iannone LF, Arena G, Battaglia D. Results Fr om an Italian Expande d Access Program on 
Cannabidiol Treatment in Highly Refractory Dravet S yndrome and Lennox-Gastaut 
Syndrome. Front Neurol. 2021 May 20;12:673135. doi: 10.3389/fneur.2021.673135. 
14. Sharbaf Shoar N, Fariba KA, Pa dhy RK. Citalopram. StatPearls 
https://www.ncbi.nlm.nih.gov/books/NBK482222/ 
15. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, 
Wilke RA, Avigan M, Kaplowitz N, Bjor nsson E, Daly AK. Case definition and 
phenotype standardization in  drug-induced liver injury. Clin Pharmacol Ther. 2011 
Jun;89(6):806-15. doi: 10.1038/clpt.2011.58. Epub 2011 May 4. PMID: 21544079. 
16. Arnold JC, McCartney D, Suraev  A, McGregor IS. The safety and efficacy of low oral 
doses of cannabidiol: An evaluation of the evidence. Clin Transl Sci. 2023 Jan;16(1):10-
30. doi: 10.1111/cts.13425. Epub 2022 Oct 19. PMID: 36259271 
 
 
   
 
 
 
CONFIDENTIAL Page 59of 728. APPENDICES
Appendix A – Schedule of Events – Part 1

 
CONFIDENTIAL Page 60 of 72 
  
  
  
CONFIDENTIAL Page 61of 72

CONFIDENTIAL Page 62of 72Appendix B – Schedule of Events – Part 2.1 (Citalopram)

CONFIDENTIAL Page 63of 72

CONFIDENTIAL Page 64of 72Appendix B – Schedule of Events – Part 2.2 (Morphine) 

CONFIDENTIAL Page 65of 72

 
 Appendix C – List of Abbreviations 
LIST OF ABBREVIATIONS 
Abbreviation Definition 
AE adverse event 
Ag/Ab antigen/antibody 
AUC  area under the concentration time curve  
BID twice daily CDC Center for Disease Control CFR Code of Federal Regulations CI confidence interval 
C
max maximum observed concentration 
COVID-19 coronavirus disease of 2019 CV coefficient of variation CYP cytochrome P450 ECG electrocardiogram 
eCRF electronic case report form 
FDA Food and Drug Administration GCP Good Clinical Practice HBsAg hepatitis B surface antigen HepC hepatitis C 
HIPAA Health Insurance Portability and Accountability Act 
HIV human immunodeficiency virus ICH International Council for Harmonisation IRB Institutional Review Board IV Intravenous 
K
el elimination rate 
Kg kilogram LH Luteinizing Hormone MedDRA Medical Dictionary for Regulatory Activities Mg milligram 
NSAID nonsteroidal anti-inflammatory drug 
OTC over-the-counter PD PVD Pharmacodynamic 
Pharmacovigilance Department  
PK pharmacokinetic 
QA quality assurance 
QD once daily QTc heart rate-corrected QT interval SAE serious adverse event SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 
SAP statistical analysis plan 
SD standard deviation SOP standard operating procedure t
1/2TEAE terminal half-life treatment-emergent adverse event 
 
 
 Appendix D – Drug-Induced Liver Injury Assessment 
The threshold criteria for definition of a case DILI as well as the severity grading score 
are listed below15. 
Definitions for DILI include one of the following thresholds: 
i)  5 × ULN elevation in ALT (ULN for ALT is 33 U/L for males and 25 
U/L for females) OR 
ii)  2 × ULN elevation in ALP (with accompanying elevations of 
GGT in the absence of known bone pathology driving the rise in ALP level) OR 
iii)  3 × ULN elevation in ALT and simultaneous elevation of bilirubin 
concentration exceeding 2 × ULN 
Severity grading of DILI based on the In ternational DILI Expert Working Group’s 
severity index (4-point scale): 
1. Mild: ALT  5 × ULN or ALP  2 × ULN and TBL < 2 × ULN 
2. Moderate: ALT  5 × ULN or ALP  2 × ULN and TBL  2 × ULN, or 
symptomatic hepatitis 
3. Severe: ALT  5 × ULN or ALP  2 × ULN and TBL  2 × ULN, and 
symptomatic hepatitis and 1 of the following criteria: 
- ,15  
- Ascites and/or encepha lopathy, disease duration < 26 weeks, and 
absence of underlying cirrhosis 
- Other organ failure due to DILI 
4. Fatal/transplantation: Death or liver transplantation due to DILI 
 
 
 
 
 
  
 
 
 Appendix E – Protocol Revision History 
PROTOCOL REVI SION HISTORY 
Protocol 
Number Version Effective 
Date Summary of Changes 
SCR-016 1.0 08 December 
2023 1. Developed initial protocol 
SCR-016 2.0 21 December 
2023 1.  Typographical changes made throughout the 
protocol. 
2. Principal investigator  updated to Dr. Melanie 
Fein, MD.  
3. Part 1 exploratory end point added: “Summary 
of CBD and metabolite pharmacokinetics.” 
4. Part 2 exploratory endpoint added: “PK 
parameters for CBD and metabolites.”  
5. For Key Exclusion Criteria #1, the threshold for 
International Normalized Ratio (INR) changed from 1.27 to 1.3.  
6. For section 3.1: 
x Part 1 explorator y endpoint removed 
“Change from baseline in additional laboratory tests after CBD administration compared to placebo.”  
7. For section 4.1.1 Risk/Benefit: 
x The following text removed: “For AEs, 
acetaminophen 1000 mg q8 hours, as 
needed, will be provided.”  
8. For section 4.2.2: 
x exclusion criteria #8 updated to “Subject 
has a positive test result for alcohol or drugs of misuse (amphetamines, barbiturates, benzodiazepines, cocaine, alcohol, opiates, phencyclidine, 
 
 Protocol 
Number Version Effective 
Date Summary of Changes 
propoxyphene, and methadone) at 
Screening or Check-in (Day -1 [both 
Parts]; Day 10 [morphine DDI]; Day 12 [citalopram DDI]).”  
9. For section 4.2.2: 
x exclusion criteria #9, added “Day –1” 
10. For sections 4.5 Criteria for Subject 
Withdrawal and 4.7.3.2.1  Assessment and 
Reporting of Potential Cases of Drug-Induced 
Liver Injury: 
x The following language added “When 
subject withdrawal occurs due to potential 
Drug-Induced Liver Injury (DILI), the 
study drug will be discontinued, and 
monitoring will still be continued to document subsequent liv er test results and 
resolution of bioche mical abnormalities.”  
x Follow-up liver assessment timing 
changed from to “24 to 48 hours.”  
x Language added: “The se follow-up steps 
are outlined in more detail in Supplement A: LFT Elevation Evaluation.”  
11. For section 4.5.1 Handling of Withdrawals, 
removed, “Any data and samples collected before 
subject withdrawal will become the property of 
the sponsor.” 
12. For sections 4.6.3 Screening and 4.6.4.1 
Check-In (Day -1):  
x “Cannabinoids (THC)” added to list of 
drugs screened for.  
x Added the following testing language: 
“Perform FSH assessment 
 
 Protocol 
Number Version Effective 
Date Summary of Changes 
(postmenopausal [i.e., spontaneous 
amenorrhea for at least 12 months] female 
subjects only).”      
13. For section 4.6.4.1 Check-in (Day –1) and Part 
1 SOE, complete physical exam changed to targeted physical exam and a weight collection 
added to list of assessments. 
14.  For section 4.7.2 Lipid Assessments, added 
“Lipid assessments will include total cholesterol, 
LDL, HDL, and triglycerides.”  
15. For section 4.8.7 Subject Restrictions and 
4.2.2 Exclusion criteria, ka va melatonin and St 
Johns Wart added to list of exclusion criteria and 
restricted supplements.   
16. For section 4.9.2 Analysis Populations, added 
the following language: 
x “...with the substrate drug alone and with 
the substrate drug in combination with 
CBD.” 
17. For section 4.9.6 Additional Analyses, added: 
x “...the following categorical and visual 
summaries.” 
x “Steady state CBD and metabolite drug 
concentrations will be summarized by visit using descriptive statistics.” 
18. Appendix B updated to accurately reflect 
events. 
SCR-016 3.0 19th March 
2024 1. For synopsis and section 4.1 Study Design, 
added the language “…to remind subjects regarding their requirements for…” 
 
 Protocol 
Number Version Effective 
Date Summary of Changes 
2. For section 4.2.1 Inclusion Criteria, added 
“Day -1” to inclusion number 2 and 4. 
3. For section 4.2.2 Exclusion Criteria, exclusion 
#1 was updated to include “screening or check-in (Day -1)” and #12 was further updated to add “a dia gnosis of COVID-19” 
4. For section 4.2.2 Exclusion Criteria, exclusion 
#16 added “Uncomplicated cholecystectomies 
and appendectomies may be included at the 
investigator’s discretion.” 
5. For section 4.2.2 Exclusion Criteria, blood 
pressure values updated to the following: “Subject has a mean systolic blood pressure 
<85 or >145 mmHg or a mean diastolic blood 
pressure <45 or >95 mmHg  at either Screening 
or Check-in.   
6. For section 4.6.4.2 Treatment, “Collect whole 
blood sample for pharm acogenetic testing 
(Only Part 2)” was a dded and removed from 
4.6.4.1 Check-in 
7. For section 4.6.4.2 Treatment, added 
“Administration of study drug [Part 1: clinic 
visits and Day 28, Part 2: Day 12 (citalopram) 
and Day 10 (morphine)] can occur prior to review of safety labs.” 
8. For section 4.7.1.1 Pharm acokinetic Sample 
Collection “ Clinic visits may be completed 
outside of the listed vis it day per investigator’s 
decision.” And “ All lab collections will take 
place predose and within 1 hour of mealtime” 
was added.  
 
  Protocol 
Number Version Effective 
Date Summary of Changes 
9. For section 4.7.3.3 Vital Sign Measurements, 
added “Vital signs may be repeated at 
investigator discretion.” 
10. For section 4.8.6 Prior and Concomitant 
Medications, removed “oral” from “oral 
contraceptives” and added “During the study, 
low dose acetaminophen or ibuprofen may be 
allowed with investigat or’s approval for minor 
symptoms.” 
11. For Appendix A and B Schedule of Events and 
Section 4.6.4.1, pharmacoge netic testing was 
removed 
12. For Appendix A and B Schedule of Events, 
“PCR” removed from Covid testing 
Certificate Of Completion
Envelope Id: C85DFB632C524FC8877B2D686753630D Status: Completed
Subject: Complete with DocuSign: CBD Study Protocol Version 3 March 18 2024 Clean.pdfSource Envelope: Document Pages: 72 Signatures: 2 Envelope Originator: Certificate Pages: 5 Initials: 0 Karrielynn GerlachAutoNav: EnabledEnvelopeId Stamping: DisabledTime Zone: (UTC-08:00) Pacific Time (US & Canada)Karrielynn.Gerlach@spauldingclinical.com
IP Address: 208.87.126.49
Record Tracking
Status: Original             3/20/2024 9:29:29 AMHolder: Karrielynn Gerlach
             Karrielynn.Gerlach@spauldingclinical.comLocation: DocuSign
Signer Events Signature Timestamp
David Strauss
david.strauss@fda.hhs.govSponsor Study LeadSecurity Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signature ID: 
C37632FD-56B7-47FC-9B70-FAEE64302722
Using IP Address: 150.148.14.141
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this documentSent: 3/20/2024 9:34:05 AM
Resent: 3/21/2024 9:53:29 AMViewed: 3/21/2024 9:56:11 AM Signed: 3/21/2024 9:56:34 AM
Electronic Record and Signature Disclosure: 
      Accepted: 10/25/2021 11:15:54 AM
      ID: 51a3664d-cfbd-4295-b370-e0bb8628e897
Melanie Fein
melanie.fein@spauldingclinical.comDirector of Medical Strategy and OversightSpaulding Clinical Research
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signature ID: 
9F4570AC-496B-4E36-80B1-0886E4D3A4DD
Using IP Address: 24.167.164.111
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):    I approve this documentSent: 3/21/2024 9:56:37 AM
Viewed: 3/21/2024 10:49:38 AM Signed: 3/21/2024 10:50:03 AM
Electronic Record and Signature Disclosure: 
      Not Offered via DocuSign
In Person Signer Events Signature Timestamp
Editor Delivery Events Status Timestamp
Agent Delivery Events Status Timestamp
Intermediary Delivery Events Status Timestamp
Certified Delivery Events Status Timestamp
Carbon Copy Events Status Timestamp
Witness Events Signature Timestamp
Notary Events Signature Timestamp
Envelope Summary Events Status Timestamps
Envelope Sent Hashed/Encrypted 3/20/2024 9:34:05 AM
Certified Delivered Security Checked 3/21/2024 10:49:38 AMSigning Complete Security Checked 3/21/2024 10:50:03 AMCompleted Security Checked 3/21/2024 10:50:03 AM
Payment Events Status Timestamps
Electronic Record and Signature Disclosure
ELECTRONIC RECORD AND SIGNATURE DISCLOSURE   
From time to time, Spaulding Clinical (we, us or Company) may be required by law to provide to 
you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully  and thoroughly, and if you can access this 
information electronically to your satisfaction and agree to this Electronic Record and Signature 
Disclosure (ERSD), please confirm y our agreement by selecting the check- box next to ‘I agree to 
use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign 
system. 
 
Getting paper copies   
At any time, you may request from us a paper copy of any record provided or made available 
electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may acce ss the documents for a limited period of time 
(usually 30 days) after such documents are first sent to you. After such time, if you wish for us to 
send you paper copies of any such documents fr om our office to you, you will be charged a 
$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below. 
 
Withdrawing your consent   
If you decide to receive notices and disclosure s from us electronically, you may at any time 
change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below. 
 
Consequences of changing your mind   
If you elect to receive required notices and disclosures only in paper format, it will slow the 
speed at which we can complete certain steps in tr ansactions with you and delivering services to 
you because we will need first to send the required notices or disclosures to you in paper format, 
and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us. 
 
All notices and disclosures will be sent to you electronically   

 	




Unless you tell us otherwise in accordance with the procedures described herein, we will provide 
electronically to you through the DocuSign system all required notices, disclosures, 
authorizations, acknowledgements, and other documen ts that are required to be provided or made 
available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same meth od and to the same address that you have given 
us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the pa ragraph immediately above  that describes the 
consequences of your electing not to receive delivery of the notices and disclosures electronically from us. 
 
How to contact Spaulding Clinical:   
You may contact us to let us know of your changes as to how we may contact you electronically, 
to request paper copies of certain information fr om us, and to withdraw your prior consent to 
receive notices and disclosures electronically as follows: To contact us by email send messages to: jeffrey.sanchez@spauldingclinical.com 
 
To advise Spaulding Clinical of your new email address   
To let us know of a change in your email address where we should send notices and disclosures 
electronically to you, you must send an email message to us 
at jeffrey.sanchez@spauldingclinical.com and in the body of such request you must state: your 
previous email address, your new email address.  We do not require any other information from 
you to change your email address.  
If you created a DocuSign account, you may update it with your new email address through your 
account preferences.  
 
To request paper copies from Spaulding Clinical   
To request delivery from us of paper copies of  the notices and disclosures previously provided 
by us to you electronically, you must send us an email 
to jeffrey.sanchez@spauldingclinical.com and in the body of such request you must state your 
email address, full name, mailing addr ess, and telephone number. We will bill you for any fees at 
that time, if any. 
 
To withdraw your consent with Spaulding Clinical   
To inform us that you no longer wish to receive future notices and disclosures in electronic 
format you may: 
i. decline to sign a document from within your signing session, and on the subsequent page, 
select the check-box indicating you wish to withdraw your consent, or you may; 
ii. send us an email to jeffrey.sanchez@spauldingc linical.com and in the body of such request 
you must state your email, full name, mailing address, and telephone number. We do not need 
any other information from you to withdraw consent..  The consequences of your withdrawing consent for online documents will be that tran sactions may take a longer time to process.. 
 
Required hardware and software   
The minimum system requirements for using the DocuSign system may change over time. The 
current system requirements are found here: https://support.docusign.com/guides/signer-guide-
signing-system-requirements .  
 
Acknowledging your access and consent to receive and sign documents electronically   
To confirm to us that you can access this information electronically, which will be similar to 
other electronic notices and disclosures that we wi ll provide to you, please confirm that you have 
read this ERSD, and (i) that you are able to prin t on paper or electronically save this ERSD for 
your future reference and access; or (ii) that you are able to email this ERSD to an email address 
where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check- box next to ‘I agree to use electronic records and signatures’ before 
clicking ‘CONTINUE’ within the DocuSign system.  
By selecting the check- box next to ‘I agree to use electronic records and signatures’, you confirm 
that: 
x You can access and read this Electronic Record and Signature Disclosure; and 
x You can print on paper this Electronic Record and Signature Disclosure, or save or send 
this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and 
x Until or unless you notify Spaulding Clinical as  described above, you consent to receive 
exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that  are required to be provided or made 
available to you by Spaulding Clinical during the course of your relationship with 
Spaulding Clinical. 